

FLAVONOIDS AND PHENOLICS



Editor:
Simone Carradori

Bentham Books

Medicinal Chemistry Lessons From Nature

(Volume 1)

Flavonoids and Phenolics

Edited By

Simone Carradori

Department of Pharmacy, G. d'Annunzio

University of Chieti-Pescara

Italy

Medicinal Chemistry Lessons From Nature

Volume # 1

Flavonoids and Phenolics

Editor: Simone Carradori

ISSN (Online): 2972-340x

ISSN (Print): 2972-3396

ISBN (Online): 978-981-5079-09-8

ISBN (Print): 978-981-5079-10-4

ISBN (Paperback): 978-981-5079-11-1

©2022, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2022.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

FOREWORD	i
KEY FEATURES	i
PREFACE	ii
LIST OF CONTRIBUTORS	iii
CHAPTER 1 POLYPHENOLS AND FLAVONOIDS: CHEMICAL, PHARMACOLOGICAL AND THERAPEUTIC ASPECTS	1
<i>Stefania Cesa, Francesco Cairone and Celeste De Monte</i>	
INTRODUCTION	1
CHEMICAL STRUCTURES, CLASSIFICATION AND PROPERTIES OF FLAVONOIDS	4
Classes of Flavonoids with the B Ring on C2	5
Classes of Flavonoids with the B Ring on C3	7
Classes of Flavonoids Where the B Ring is Connected to the C Ring Through the 4th Position	7
Classes of Open-Chain Flavonoids	7
PHARMACOLOGICAL ASPECTS OF POLYPHENOLS AND FLAVONOIDS	8
BIOAVAILABILITY AND METABOLISM OF FLAVONOIDS, TOXICOLOGICAL ACTIVITY AND SEMI-SYNTHETIC STRATEGIES	14
ADME of Flavonoids	14
Factors that Could Affect ADME of Flavonoids	16
Toxicity of Flavonoids	18
Strategies for a Better Investigation of Flavonoids Properties	18
CONCLUSION	19
CONSENT FOR PUBLICATION	19
CONFLICT OF INTEREST	19
ACKNOWLEDGEMENTS	20
REFERENCES	20
CHAPTER 2 RECENT DEVELOPMENT OF HYBRIDS AND DERIVATIVES OF RESVERATROL IN NEURODEGENERATIVE DISEASES	27
<i>Barbara De Filippis and Marialuigia Fantacuzzi</i>	
INTRODUCTION	27
MULTITARGET ANALOGUES OF RSV	32
Hybrids of RSV	32
Derivatives of RSV	52
<i>Schiff Base Derivatives of RSV</i>	55
CONCLUDING REMARKS	59
ABBREVIATIONS:	61
CONSENT FOR PUBLICATION	61
CONFLICT OF INTEREST	61
ACKNOWLEDGEMENTS	61
REFERENCES	61
CHAPTER 3 BIOLOGICAL ACTIVITIES OF SYNTHETIC DERIVATIVES OF XANTHONES: AN UPDATE (2016-2020)	73
<i>Cristina Scarpecci and Sara Consalvi</i>	
INTRODUCTION	73
XANTHONE SYNTHETIC DERIVATIVES FOR CANCER THERAPY	74
Caged Xanthones (CXs)	75
Mangostin Analogs	81

Carboxyxanthonones	83
Dihydroxyxanthonones	85
N-Xanthone Benzenesulphonamides	86
Dioxygenated Xanthonones	88
Xanthonones Bearing Long Side Chains	89
ANTIBACTERIAL XANTHONE SYNTHETIC DERIVATIVES	91
Amphiphilic Xanthonones	91
Amino Acid-Conjugated Xanthonones	94
Miscellaneous Compounds	96
ANTIFUNGAL XANTHONE SYNTHETIC DERIVATIVES	97
ANTIMALARIAL XANTHONE SYNTHETIC DERIVATIVES	99
XANTHONE SYNTHETIC DERIVATIVES AS ANTI-INFLAMMATORY AGENTS	100
ANTI-ALZHEIMER XANTHONE SYNTHETIC DERIVATIVES	101
XANTHONE SYNTHETIC DERIVATIVES AS A-GLUCOSIDASE INHIBITORS	103
CONCLUDING REMARKS	105
CONSENT FOR PUBLICATION	105
CONFLICT OF INTEREST	106
ACKNOWLEDGEMENT	106
REFERENCES	106
CHAPTER 4 COMBRETASTATIN DERIVATIVES AS TUBULIN INHIBITORS: A FASCINATING JOURNEY FROM NATURE TO DRUG DISCOVERY STRATEGIES	112
<i>Alessandra Ammazalorso and Trond Vidar Hansen</i>	
INTRODUCTION	113
INSIGHTS ON MECHANISM OF ACTION OF COMBRETASTATINS	114
Development of Combretastatin Prodrugs	115
Fosbretabulin, Ombrabulin and Oxi4503	116
Combretastatin Prodrugs With Improved Drug Delivery Ability	117
Bioreductive Prodrugs of Combretastatins	119
Photoresponsive Hybrid Prodrugs of Combretastatins	120
DEVELOPMENT OF COMBRETASTATIN DERIVATIVES	122
Combretastatin Derivatives Obtained by Bridge Modifications	123
<i>Carbocyclic Derivatives</i>	<i>124</i>
<i>Heterocyclic Derivatives</i>	<i>125</i>
RECENT ADVANCES IN DRUG DELIVERY SYSTEMS OF COMBRETASTATIN	132
CONCLUDING REMARKS	137
ABBREVIATIONS	137
CONSENT FOR PUBLICATION	138
CONFLICT OF INTEREST	138
ACKNOWLEDGEMENT	138
REFERENCES	138
CHAPTER 5 NATURAL FLAVONOID AND CHALCONE SCAFFOLDS AS LEADS FOR SYNTHETIC ANTITUBERCULAR AGENTS	145
<i>Federico Appetecchia, Mariangela Biava and Giovanna Poce</i>	
INTRODUCTION	145
FLAVONOIDS	147
Chalcones	149
Simple-substituted Chalcones	150
Heteroaryl and Hybrid Chalcones	152
CONCLUDING REMARKS	166
CONSENT OF PUBLICATION	167

CONFLICT OF INTEREST	167
ACKNOWLEDGMENT	167
REFERENCES	167
CHAPTER 6 IN SILICO APPROACHES TO NATURALLY EXISTING CHALCONES AND FLAVONOIDS ON MAO INHIBITORY ACTION: A BOON TO CNS DRUG DISCOVERY	173
<i>Arafa Musa, Della Grace Thomas Parambi, Mutairah Shaker Alshammari, Rania Bakr, Mohammed A. Abdelgawad, Dibya Sundar Panda, Manoj Kumar Sachidanandan, Vaishnav Bhaskar, Leena K. Pappachen and Bijo Mathew</i>	
INTRODUCTION	174
CHALCONES	175
Prenylated Chalcone: Xanthoangelol and 4-Hydroxyderricin	176
Resveratrol	177
Dihydrochalcones	178
Flavonoids	178
Quercetin	179
Xanthones	180
Homoisoflavonoids	180
Thioflavones	181
Sideritis Flavonoids	182
Studies on Apigenin, Kaempferol, Quercetin and Luteolin	183
PRENYLAPIGENIN	184
Bavachinin and Bavachin	185
Genistein	186
Phytochemicals from Clitoria Ternatea	187
O-Methylated Flavonoids	187
CONCLUDING REMARKS	189
CONSENT FOR PUBLICATION	190
CONFLICT OF INTEREST	190
ACKNOWLEDGEMENTS	190
REFERENCES	190
CHAPTER 7 LIGNINS AND LIGNANS – RECENT DEVELOPMENTS AND TRENDS REGARDING THEIR PHARMACEUTICAL PROPERTIES	196
<i>Luc Zongo and Heiko Lange</i>	
INTRODUCTION	196
LIGNIN	197
Biosynthesis and Structural Features of Lignins	197
Isolation of Lignins	202
Lignin Fractionation	202
LIGNANS	203
Biosynthesis and Structural Features of Lignans	203
ANALYTICAL TOOLS FOR ANALYSES OF LIGNINS AND LIGNANS	206
Fourier-Transform Infrared Spectroscopy and Raman Spectroscopy	206
NMR Spectroscopy-Based Analysis Methods	206
Size Exclusion and Gel Permeation Chromatographic Methods	207
Mass Spectrometry Methods	208
Anti-Oxidant Activity Assays	208
LIGNINS FOR USE IN PHARMACEUTICAL AREA	209
Lignin as Source of Pharmaceutical Activity	209
LIGNIN AS MATERIAL FOR MICRO- AND NANOSTRUCTURES FOR PHARMACEUTICAL USE	211

Lignin-Containing Film Preparations for Pharmaceutical Applications	211
NANOPARTICLES	212
Micro- and Nanoscaled Core-shell Structures	213
Incorporation of Actives in Lignin Particle and Lignin Capsule Structures	214
Entrapment <i>Vs.</i> Encapsulation <i>Vs.</i> Adsorption	215
Covalent and Electrostatic Surface Functionalisation	218
PHARMACEUTICAL PROPERTIES OF LIGNANS	219
Dietary Value of Lignans in Health Promotion	220
Antiaging Potential of Lignans	220
Anti-Inflammatory Properties of Lignans	221
Anticancer Properties of Lignans	223
Antibiotic Properties of Lignans	224
Antiviral Properties of Lignans	224
Hepatoprotective Effects of Lignans	225
The Neuroprotective Effects of Lignans	226
The Physicochemical Properties of Lignans in Drug Design	226
CONCLUDING REMARKS AND FUTURE PERSPECTIVES	227
CONSENT FOR PUBLICATION	228
CONFLICT OF INTEREST	228
ACKNOWLEDGEMENT	228
REFERENCES	228
CHAPTER 8 SEMISYNTHETIC RESVERATROL-DERIVED SYSTEMS: A SYNERGISM BETWEEN NATURE AND ORGANIC SYNTHESIS	249
<i>Antonella Capperucci and Damiano Tanini</i>	
INTRODUCTION	249
RESVERATROL ETHERS AND RELATED DERIVATIVES	250
Resveratryl Esters and Related Derivatives	256
Selenium-containing Resveratrol Derivatives	261
Resveratrol-Derived Hybrids and Other Conjugates	263
CONCLUSION	267
CONFLICT OF INTEREST	267
ACKNOWLEDGEMENT	267
CONSENT OF PUBLICATION	267
REFERENCES	268
CHAPTER 9 AURONE SCAFFOLD AND STRUCTURAL ANALOGUES FOR THE DEVELOPMENT OF MONOAMINE OXIDASE (MAO) INHIBITORS	272
<i>Paolo Guglielmi, Virginia Pontecorvi and Atilla Akdemir</i>	
INTRODUCTION	272
AURONES AND THEIR STRUCTURAL-RELATED COMPOUNDS	276
Aurones	277
Indanone and Tetralone Derivatives	283
Homoisoflavonoids Derivatives (3-Benzylidenechroman-4-ones)	289
CONCLUSION	293
CONSENT FOR PUBLICATION	294
CONFLICT OF INTEREST	294
ACKNOWLEDGEMENT	294
REFERENCES	294
CHAPTER 10 COUMARINS AS CARBONIC ANHYDRASE INHIBITORS	298
<i>Claudiu T. Supuran</i>	
CARBONIC ANHYDRASE INHIBITORS AND ACTIVATORS	298

COUMARINS WITH CA INHIBITORY ACTION	300
Natural Product Coumarins	300
Synthetic Coumarins	308
Other Drug Design Studies using Coumarins as Lead Molecules	317
CONCLUSIONS	321
CONSENT FOR PUBLICATION	321
CONFLICT OF INTEREST	321
ACKNOWLEDGEMENTS	321
REFERENCES	322
CHAPTER 11 PHENOLS AND POLYPHENOLS AS CARBONIC ANHYDRASE INHIBITORS	330
<i>Alessandro Bonardi, Claudiu T. Supuran and Alessio Nocentini</i>	
PHENOLS AND POLYPHENOLS	330
Carbonic Anhydrases	331
CA Inhibition Mechanism of Phenol Derivatives	331
Phenolic Derivatives Inhibit Human CAs	334
Synthetic/Semisynthetic Phenolic Derivatives as Hcas Inhibitors	346
Natural and Synthetic/Semisynthetic Phenols Inhibit Carbonic Anhydrases From Bacteria, Fungi, Protozoa, And Diatoms	360
<i>In Silico</i> Studies of the Binding Mode of Phenolic Derivatives to CA Isoforms	369
CONCLUSION	373
CONSENT FOR PUBLICATION	373
CONFLICT OF INTEREST	373
ACKNOWLEDGEMENT	373
REFERENCES	373
CHAPTER 12 THE ROLE OF FLAVONOIDS AND OTHER SELECTED (POLY) PHENOLS IN CANCER PREVENTION AND THERAPY: A FOCUS ON EPIGENETICS	384
<i>Melissa D'Ascenzio</i>	
INTRODUCTION	384
Chemoprevention and the Epigenetic Mechanisms Associated with Chronic Diseases	384
EPIGENETIC MARKS AND EPIGENETIC PROTEINS	387
DNA Methyltransferases	387
Histone Acetyl Transferases (Hats) and Histone Deacetylases (Hdacs)	387
Histone Methyl Transferases (Hmts)	388
Other Post-Translational Modifications	391
FLAVONOIDS AS EPIGENETIC MODULATORS IN CHEMOPREVENTION AND CANCER THERAPY	392
FLAVONOLS, FLAVONES, ISOFLAVONES, AND ANTHOCYANINS	395
Flavonols: Quercetin and Kaempferol	395
Flavones: Apigenin, Luteolin and Chrysin	407
Isoflavones: Genistein and Daidzein	412
Anthocyanins	419
Flavanols: Catechins from Green Tea	424
CURCUMIN AND CURCUMINOIDS	437
RESVERATROL AND OTHER STILBENE DERIVATIVES	453
CONCLUDING REMARKS	468
CONSENT FOR PUBLICATION	468
CONFLICT OF INTEREST	469
ACKNOWLEDGEMENTS	469
REFERENCES	469
SUBJECT INDEX	490

FOREWORD

The intention of this volume is to give an overview of the latest discoveries in the research on natural products-derived compounds, through a medicinal chemistry approach of the most exciting topics on flavonoids and (poly)phenolics derivatives. It is structured with innovative book setting outlines and a clear distinction between experimental and clinical results, in order to aid the reader to know at which step of the pipeline each compound is. Due to the scarcity of information of the other competing books, the Guest Editor wants to fulfil the gap of the acquired knowledge in the last few years with the aim to provide a guide for academic and professional researchers and clinicians.

The exploration of the chemical space ranges from flavonoids to phenolic compounds, covering all the aspects relevant for medicinal chemistry (drug design, structure-activity relationships, permeability data, cytotoxicity, appropriate statistical procedures, molecular modelling studies and technological formulations). Each chapter reviews on agents with common chemical features, considering them as scaffolds to obtain various derivatives aiming at the biological activity. The chemical modifications of these agents could increase their intrinsic properties, overcome limitations as drug candidates and introduce new properties. Thus, the volume is intended to be useful to researchers for more concrete applications in the natural product field. As far as I know, this is the first time these data are organized focusing on the synthetic methods and their strategies comprehending the last years.

KEY FEATURES

1. Updated information on synthetic/natural compounds;
2. In-depth analysis of novel findings and promising translational applications;
3. Use of organic reactions as a powerful tool in drug discovery to improve the biological activity or give new chemical and biological properties to the parent molecules;
4. Molecular mechanisms with innovative approaches for the readers to improve their own research investigations.

Rosa Amoroso
Department of Pharmacy
G. d'Annunzio University of Chieti-Pescara
Via dei Vestini 31, 66100 Chieti (Italy)

PREFACE

Natural products are often used in drug development due to their ability to provide unique and chemically diverse structures unmatched by any synthetic chemical collection. Medicinal Chemists have always been inspired by nature because natural products are often perceived as safer and for their capability to interact with biological targets. Indeed, in recent years, there has been emerging research on traditional herbal medicines based on their efficacy in the treatment of diseases for which they have been traditionally applied.

Conversely, natural compounds suffer from several issues such as scarce availability and seasonality, high differences in the production/extraction/isolation, low purity in commercial products from worldwide suppliers, and side effects. Moreover, due to their chemical complexity and the optional presence of different chiral centers, the total synthesis of a natural compound can be also challenging and expensive.

This book series would propose the latest discoveries in the field of compounds inspired by nature and obtained by chemical/enzymatic modification of a natural compound in the search for biologically active molecules for the treatment of human/animal ailments and permit the disposal of a wider arsenal for clinicians. The natural compounds are grouped into three clusters. The chapters are built in the following format: • General background on the (phyto)chemistry of the scaffold; • General background on the pharmacological profile of the scaffold; • Description of the proposed derivatives and their potentialities with respect to the parent compounds (with a particular emphasis on the synthetic approaches and structure-activity relationships); • *In silico* analysis of the crucial interactions with the biological target, when available; • Clinical studies and patent surveys (if available) on the new and proposed structures.

The readership of this book is represented primarily by Academies, Researchers, Specialists in the pharmaceutical field, Industry sector, Contract Research Organizations and hospitals dealing with clinical research.

Simone Carradori
Department of Pharmacy
G. d'Annunzio University of Chieti-Pescara
Italy

List of Contributors

- Adriana Trifan** Department of Pharmacognosy, Faculty of Pharmacy, “Grigore T. Popa” University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania
- Alessandra Ammazalorso** Department of Pharmacy, Medicinal Chemistry Unit, “G. d’Annunzio” University of Chieti-Pescara, *Via dei Vestini*, 66100 Chieti, Italy
- Alessandro Bonardi** Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, Pharmaceutical and Nutraceutical Section, University of Florence, *Via U. Schiff 6*, 50019 Sesto Fiorentino, Firenze, Italy
- Alessio Nocentini** Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, Pharmaceutical and Nutraceutical Section, University of Florence, *Via U. Schiff 6*, 50019 Sesto Fiorentino, Firenze, Italy
- Andrea Angeli** Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, Pharmaceutical and Nutraceutical Section, University of Florence, *Via U.*, Schiff 6, 50019 Sesto Fiorentino, Firenze, Italy
- Annabella Vitalone** Department of Physiology and Pharmacology “V. Ersparmer”, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy
- Antonella Capperucci** Department of Chemistry “Ugo Schiff”, University of Florence, *Via della Lastruccia 13*, I-50019 Sesto Fiorentino, Italy
- Antonella Di Sotto** Department of Physiology and Pharmacology “V. Ersparmer”, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy
- Arafa Musa** Department of Pharmacognosy, College of Pharmacy, Jouf University, Sakaka, Al Jouf, 2014, Saudi Arabia
- Arafa Musa** Department of Pharmacognosy, College of Pharmacy, Jouf University, Sakaka, Al Jouf, 2014, Saudi Arabia
- Atila Akdemir** Computer-aided Drug Discovery Laboratory, Department of Pharmacology, Faculty of Pharmacy, Bezmialem Vakif University, Fatih, Istanbul 34093, Turkey
- Barbara De Filippis** Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, *Via dei Vestini 31*, 66100 Chieti, Italy
- Bijo Mathew** Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Amrita Health Science Campus, Kochi-682 041, India
- Celeste De Monte** Department of Drug Chemistry and Technology, Sapienza, University of Rome, 00185 Rome, Italy
- Claudio Ferrante** Department of Pharmacy, Medicinal Plant Unit (MPU), Botanic Garden Giardino dei Semplici, G. d’Annunzio University of Chieti-Pescara, *Via dei Vestini*, 66100 Chieti, Italy
- Claudiu T. Supuran** Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, Pharmaceutical and Nutraceutical Section, University of Florence, *Via U. Schiff 6*, 50019 Sesto Fiorentino, Firenze, Italy

Giovanna Poce	Department of Drug Chemistry and Technology, Sapienza, University of Rome, 00185 Rome, Italy
Heiko Lange	Department of Environmental and Earth Sciences, University of Milano-Bicocca, Milan, Italy
Leena K Pappachen	Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Amrita Health Science Campus, Kochi-682 041, India
Luc Zongo	Department of Pharmacy, University of Saint Dominic of West Africa (USDAO), Doulougou, Burkina Faso
Mohamed A. Abdelgawad	Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Al Jouf, 2014, Saudi Arabia
Manoj Kumar Sachidanandan	Department of Oral and maxillofacial surgery and diagnostics, College of Dentistry, Hail University, Hail Province, 2440, Saudi Arabia
Maria Antonietta Casadei	Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy
Melissa D'Ascenzio	D'Arcy Thompson Unit, Biological and Biomedical Sciences Education, School of Life Sciences, University of Dundee, DD1 4HN, Dundee, UK
Mohammed A. Abdelgawad	Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, AlJouf, 72341, Saudi Arabia
Mutairah Shaker Alshammari	Department of Pharmaceutical Analytical Chemistry, Faculty of science, Jouf University, Sakaka, Al Jouf, 2014, Saudi Arabia
Paolo Guglielmi	Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy
Rania Bakr	Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Al Jouf, 2014, Saudi Arabia
Sara Consalvi	Department of Drug Chemistry and Technology, Sapienza, University of Rome, 00185 Rome, Italy
Stefania Cesa	Department of Drug Chemistry and Technology, Sapienza, University of Rome, 00185 Rome, Italy
Stefania Garzoli	Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy
Stefania Petralito	Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy
Trond Vidar Hansen	Department of Pharmacy, Section for Pharmaceutical Chemistry, University of Oslo, PO Box 1068 Blindern, N-0316 Oslo, Norway
Virginia Pontecorvi	Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy
Vaishnav Bhaskar	Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Amrita Health Science Campus, Kochi-682 041, India

Leena K Pappachen	Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Amrita Health Science Campus, Kochi-682 041, India
Luc Zongo	Department of Pharmacy, University of Saint Dominic of West Africa (USDAO), Doulougou, Burkina Faso
Luigi Menghini	Department of Pharmacy, Medicinal Plant Unit (MPU), Botanic Garden “Giardino dei Semplici”, “G. d’Annunzio” University of Chieti-Pescara, <i>Via dei Vestini</i> , 66100 Chieti, Italy
Mohamed A. Abdelgawad	Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Al Jouf, 2014, Saudi Arabia
Manoj Kumar Sachidanandan	Department of Oral and maxillofacial surgery and diagnostics, College of Dentistry, Hail University, Hail Province, 2440, Saudi Arabia
Marco Gulli	Department of Physiology and Pharmacology “V. Ersparmer”, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy
Maria Antonietta Casadei	Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy
Marialuigia Fantacuzzi	Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, <i>Via dei Vestini</i> 31, 66100 Chieti, Italy
Mariangela Biava	Department of Drug Chemistry and Technology, Sapienza, University of Rome, P.le A. Moro 5, 00185 Rome, Italy
Mario R. Meneghetti	, Institute of Chemistry and Biotechnology, Federal University of Alagoas, Maceió, Brazil
Mattia Spano	Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy
Melissa D’Ascenzio	D’Arcy Thompson Unit, Biological and Biomedical Sciences Education, School of Life Sciences, University of Dundee, DD1 4HN, Dundee, UK
Mutairah Shaker Alshammari	Department of Pharmaceutical Analytical Chemistry, Faculty of science, Jouf University, Sakaka, Al Jouf, 2014, Saudi Arabia
Nathalie Saraiva Rosa	Department of Chemistry, Royal College of Surgeons in Ireland, Dublin, Ireland
Niccolò Chiaramonte	Department of Chemistry, Royal College of Surgeons in Ireland, Dublin, Ireland
Özlen Güzel-Akdemir	Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul University, Beyazit, 34116 Istanbul, Turkey
Paolo Guglielmi	Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy
Patrizia Paolicelli	Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy
Paulo F. Silva Santos-Júnior	Institute of Chemistry and Biotechnology, Federal University of Alagoas, Maceió, Brazil
Rafael J. M. Omena	Group of Catalysis and Chemical Reactivity, Chemistry and Biotechnology Institute, Federal University of Alagoas, Maceió, Brazil

Rania Bakr	Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Al Jouf, 2014, Saudi Arabia
Sara Consalvi	Department of Drug Chemistry and Technology, Sapienza, University of Rome, 00185 Rome, Italy
SilVia Di Giacomo	Department of Physiology and Pharmacology “V. Ersparmer”, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy
Simone Carradori	Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, <i>Via dei Vestini</i> 31, 66100 Chieti, Italy
Stefania Cesa	Department of Drug Chemistry and Technology, Sapienza, University of Rome, 00185 Rome, Italy
Stefania Garzoli	Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy
Stefania Petralito	Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy
Thiago M. Aquino	Institute of Chemistry and Biotechnology, Federal University of Alagoas, Maceió, Brazil
Trond Vidar Hansen	Department of Pharmacy, Section for Pharmaceutical Chemistry, University of Oslo, PO Box 1068 Blindern, N-0316 Oslo, Norway
Virginia Pontecorvi	Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy
Vaishnav Bhaskar	Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Amrita Health Science Campus, Kochi-682 041, India

CHAPTER 1**Polyphenols and Flavonoids: Chemical, Pharmacological and Therapeutic Aspects****Stefania Cesa^{1,*}, Francesco Cairone¹ and Celeste De Monte¹**¹ *Department of Drug Chemistry and Technology, Sapienza, University of Rome, 00185 Rome, Italy*

Abstract: Polyphenols and flavonoids represent a group of compounds characterized by a large assortment of phenolic structures, which can be naturally found in vegetables, roots, stems, flowers, grains, and fruits. Thanks to their biological activities, molecules belonging to these classes of compounds, besides their nutritional role, have found applications in several fields such as pharmaceutical, cosmetic, and nutraceutical. In fact, like many natural derivatives from plants, they possess several therapeutic properties, including antitumor, anti-oxidative, anti-neurodegenerative, antimicrobial and anti-inflammatory effects. Nowadays, the growing interest in polyphenolics and flavonoids translates into constant research to better define their pharmacological mechanism of action. Extraction studies in order to obtain pure compounds with a more defined biological activity, as well as pharmacokinetic studies to understand the bioavailability, the involved metabolic pathways and the related active metabolites, are carried out. Molecular docking studies are also continuously in progress to expand the field of application. Moreover, toxicity experiments to clarify their safety and studies about the interaction with other compounds to understand their selectivity of action are continuously forwarded and deepened. Consequently, many recent studies are aimed at introducing polyphenols, more specifically flavonoids, and their semi-synthetic derivatives, in the prevention, management and treatment of several diseases.

Keywords: Bioavailability, Biological properties, Chemical structures, Disease prevention, Flavonoids, Metabolism, Polyphenols, Semisynthetic derivatives.

INTRODUCTION

Polyphenols are the plant's secondary metabolites, contained in specialized cells in small quantities and not necessary for cell viability that vegetal organisms produce to perform different functions. They include several classes of chemical molecules characterized by the presence of aromatic rings bearing more than a hydroxylic function, up to complex polycyclic and polymeric compounds.

* **Corresponding author Stefania Cesa:** Department of Drug Chemistry and Technology, Sapienza, University of Rome, 00185 Rome, Italy; E-mail: stefania.cesa@uniroma1.it

All molecules presenting a simple phenolic group are theoretically able to act as anti-radical species since they could react with endogen radicals to undergo new and more stable radical residues, which tend to react by neutralizing rather than attacking macromolecules such as DNA or proteins causing damages up to mutagenesis or unfolding. Moreover, the presence of *ortho*-diphenol groups also allows the metals chelation, improving the antioxidant properties. Polyphenols are frequently classified in relation to their chemical structure into four principal molecules, represented by phenolic acids, flavonoids, stilbenes and lignans. Natural products have always been the subject of great interest thanks to their biological activities and pharmacological properties. The attention towards bioactive compounds is growing more and more over the years because they found applications in pharmaceutical, nutraceutical, cosmetic and medical fields [1]. By virtue of appropriate pharmacodynamic, pharmacokinetic, bioavailability and toxicity studies, they can potentially be included among dietary supplements and therapeutic tools for the prevention and treatment of many human diseases with important applications in phytotherapy and herbal medicine [2]. A recent review [3] reports the protection exerted by a polyphenol-rich diet, highlighting the potential ability of pure polyphenols and of phytoextract to reverse oxidative stress-related diseases and a “promising chemopreventive efficacy” through modulation of apoptosis and cellular growth, inhibition of DNA synthesis and modulation of signal transduction. Among the bioactive natural products, a preeminent position is occupied by flavonoids, plants and fungi secondary metabolites, of supreme interest both for their ubiquitous distribution in nature and for the wide structural diversification, to which is often correlated a specific bioactivity. They can be found in many parts of plants, including leaves, flowers (where flavonoids constitute the colored pigments of petals), roots, fruits, stems, seeds, rhizome, bark, gum and shell [4]. The reason for their ubiquitous location in many plant organs may be due to the flavonoids' important role in protecting them against oxidative stress and ultraviolet radiation, as well as in attracting pollinating animals [5].

Flavonoids have gained a special prominence among natural compounds of pharmaceutical and therapeutic interest, thanks to the wide range of chemical subclasses and their wide variety of pharmacological properties, such as the modulation of enzymatic activities by inhibiting lipid peroxidation and cyclooxygenase and lipoxygenase activity, anti-inflammatory, anti-mutagenic, antioxidative and antitumor effects [6].

In a recent review [7], authors underline the high interest, not only for polyphenols contained in several by-products of agroindustry processes but also for bound polyphenols, which could need hydrolytic treatment of the containing matrices, to make efficient their extraction yields. Analogously, Jablonsky *et al.*

[8] studied the bioactivity potential of phenolics extracted by softwood bark, emphasizing the extract complexity and the wide applications in the pharmacologic field as cytotoxic, antioxidant, fungicidal and antibacterial substances. Moreover, Cotas *et al.* [9] evaluated the potential applications of polyphenols, tannins and many others extracted from seaweed (Chlorophyta, Rhodophyta and Phaeophyceae). As polyphenols are one of the most represented classes of seaweed phytochemicals and seaweeds are one of the most available organic matrices in nature, they could be more exploited for large-scale production of polyphenolic compounds.

Healthy food containing polyphenols found also application in the prevention of skin aging and skin cancer, as functional foods or as sources of nutraceuticals to be used both in food supplements, cosmetic products or a topical formulation for dermatologic applications. This application field was also recently reviewed, but authors concluded that ingredients used with this aim, are often poorly characterised or represent part of complex mixtures by which it is difficult to establish the relationship between a single molecule and its biological effect [10].

The antioxidant and free radical scavenging activities were shown for many compounds of this class, as well as the cardioprotective, antidiabetic and antiviral potential. Most researchers are actually involved in the deepening of the mechanisms underlying the anti-cancer activity and the apoptosis induction, focusing the attention on the key enzyme involved in cellular proliferation, angiogenesis progression, and metastatic processes [11]. Anyway, most parts of these results were obtained by experiments performed *in vitro* or *ex vivo*, but the real potential of a molecule or of a class of compounds needs to be evaluated on the basis of its ability to be absorbed and metabolized while maintaining its biological effect, and finally its capability to reach the active site. As flavonoids generally display low water solubility and consequently low bioavailability, a topic of greatest interest for the scientific community is the application of several strategies aiming to solve this problem. So, a valent strategy for the polyphenolic fraction valorization is represented by the possibility of enhancing their efficacy, bioavailability and release to the action site, mediated by the exploitation of nanotechnologies capable of solving many and different problems [12] related to the specific structures, which could undergo low intestinal absorption, rapid metabolism and excretion, low plasmatic contents. This research field found application in the formulation based on many different systems, differently organized, such as liposomes, solid lipid nanoparticles, nanostructured lipid carriers, nanosuspensions, and nanoemulsions. These could be able to enhance the solubility of single nutraceuticals rather than solving problems inherent with the more or less complex nature of organic extracts obtained by food, non-edible

CHAPTER 2**Recent Development of Hybrids and Derivatives of Resveratrol in Neurodegenerative Diseases****Barbara De Filippis^{1,*} and Marialuigia Fantacuzzi¹**¹ *Department of Pharmacy, G. d'Annunzio University of Chieti-Pescara, via dei Vestini 31, 66100 Chieti, Italy*

Abstract: Neurodegenerative diseases (NDs) are characterized by the progressive loss of neurons in different regions of the nervous system, being Alzheimer's disease (AD) and Parkinson's disease (PD) the most common NDs. Despite their high incidence, the pharmacological treatments are mainly symptomatic. For this reason, in recent years, the research has been focused on the discovery of new molecules able to target neuropathological pathways involved in NDs. In the last decades, several researchers investigated the neuroprotective actions of naturally occurring polyphenols, such as resveratrol, that has attracted special interest since its ability to interact simultaneously with the multiple targets implicated in NDs. Thanks to the structural simplicity of the stilbene core, the broad spectrum of possible modifications, and the improved synthetic strategies, resveratrol is an attractive chemical starting point for the searching of new entities with extended therapeutic uses in NDs. In this review, a systematic update of the stilbene-based hybrids and derivatives, and SAR analysis were provided for the development of new drugs potentially useful as NDs multitarget directed ligands.

Keywords: Antioxidant, Molecular Hybrids, Neurodegeneration, Polyphenols, Resveratrol, Stilbene Derivatives.

INTRODUCTION

Neurodegenerative diseases (NDs) are characterized by progressive disorders and devastating damages of the structure and function of neurons. NDs etiology is still not clear, despite the increased current knowledge of their neurobiology, but different contributing factors, such as aging, lifestyle and genetic factors are involved. Despite the differences in clinical signs, among others, the pathological processes appear similar, suggesting common neurodegenerative pathways. The pathogenesis of several NDs, including Alzheimer's (AD), Parkinson's (PD),

* **Corresponding Author Barbara De Filippis:** Department of Pharmacy, G. d'Annunzio University of Chieti-Pescara, via dei Vestini 31, 66100 Chieti, Italy; E-mail: barbara.defilippis@unich.it

Huntington's (HD) and amyotrophic lateral sclerosis diseases are associated with multiple factor risks [1]. Neuroinflammation and oxidative stress represent the main causes of induction of NDs, but also excitotoxicity, mitochondrial dysfunction, and apoptosis [2]. The role of oxidative stress in neurodegeneration is well documented and is correlated to the progression of AD and PD [3]. Microglia cells are resident cells in the central nervous system (CNS), with immune function under normal conditions. The activation of brain microglia, and the subsequent extra production of inflammatory mediators, such as nitric oxide (NO), may result in uncontrolled neuroinflammation in NDs [4]. Lipoxygenase (LOX) and cyclooxygenase (COX) cascades are upregulated in chronic and age-related brain pathologies [5].

AD is the most common form of dementia and the most studied ND. It is characterized by two neuropathological hallmarks: deposition of extracellular β -amyloid ($A\beta$) plaques and intracellular neurofibrillary tangles, even if other factors as neuroinflammation play an important role in progression of AD [6]. Due to the complexity of the involved pathways, it is difficult to control the progression of this pathology. Current treatment for AD is only symptomatic; thus, the development of drugs with the potential to change the progression of the disease is a priority. One of the major pharmacological approaches of AD regards the inhibition of acetyl and butyryl cholinesterase (AChE and BuChE). They are key enzymes that play important roles in cholinergic transmission by hydrolyzing the acetylcholine (ACh) [7]. In AD, the AChE level in the brain decreases progressively, but BuChE activity remains or increases compared to the basal level. Some research studies reported that the peripheral anionic site (PAS) of AChE can locate with $A\beta$ protein and enhances the formation of amyloid fibrils in the senile plaques indicating that inhibiting the AChE activity is a promising approach to prevent $A\beta$ aggregation [8]. However, AChE inhibition may cause the classical cholinergic toxicity [9]. $A\beta_{1-42}$ is responsible for the initial self-aggregation of $A\beta$, and the resulting β -amyloid oligomers and fibrils are toxic to neurons [10]. Moreover, high concentrations of copper, zinc and iron ions accelerate amyloid deposits in AD patients [11, 12]. Although the mechanisms that underlie NDs pathophysiology are not completely clarified, a series of studies described the critical role of inflammation and oxidative stress in the degeneration of neurons [13, 14], promoting the $A\beta$ aggregation [3].

Monoamine oxidases (MAOs) have been received increasing attention in recent years due to their roles in the treatment of AD and PD. MAOs are FAD-containing enzymes that bind tightly to the outer mitochondrial membrane in brain, liver, intestinal mucosa, and other organs and catalyze the oxidative deamination of biogenic and xenobiotic amines. There are two types of isoenzymes, MAO-A and MAO-B, which can be distinguished by their

differential primary DNA sequences, tissue distribution, substrates, and inhibitor selectivity. MAO-A is situated predominantly in catecholaminergic neurons and especially oxidizes serotonin, adrenaline and noradrenaline, while MAO-B is placed in serotonergic neurons and glia where deaminates dopamine and 2-phenylethylamine (2-PEA). Therefore, the study of MAO inhibitors has attracted increasing interest in recent years for their therapeutic effect on NDs. Selective MAO-B inhibitors, such as rasagiline and selegiline, are used as adjuvant therapy in the treatment of PD and AD [15]. However, the high levels of MAO-B in neuronal tissue could lead to an increase in the levels of H₂O₂ and oxidative free radicals, which ultimately contribute to the etiology of NDs. Thus, selective inhibition of MAO-B becomes another valuable approach for the treatment of AD [16].

PD is the second most common neurodegenerative disorder caused by progressive loss of dopaminergic nigrostriatal neurons. The neuropathological hallmark of PD involves the disruption to mitochondria, the oxidative stress, alterations to the presynaptic protein α -synuclein, resulting in the accumulation of intracellular protein aggregates, Lewy bodies, and Lewy neurites, and neuroinflammatory processes [17]. Unfortunately, current drugs are mainly focused on symptomatic controls, and a long-term application leads to the loss of drug efficacy and important adverse effects. Since conventional therapeutics are not sufficient for the treatment of PD, the development of new agents is crucial [18].

Currently available drugs only provide symptomatic treatment, and has modest benefits, rather than preventing or curing neurodegeneration [19], and effective therapeutic agents are still far to success. In this contest, it is essential to develop novel therapeutic approaches to fight the NDs. Since the complexity of the involved pathways, a single biological target often proves ineffective in the treatment of diseases with a complex path mechanism. This fact inspired the research to design and develop a single drug containing structural features able to act on multiple biological targets [20]. In this way, the design of poly-pharmacophores represents a further modern approach that provides effective pharmacological responses for diverse receptors or enzymatic systems, and responds to the ADMET limits, showing antioxidant, neuroprotective, and brain permeable properties [21]. These multitarget-directed ligands (MTDLs) could contain a variety of scaffolds. During the past decades, many studies reported the positive effect of natural compounds against different diseases such as cardiovascular, diabetes, and cancer. On the other hand, natural products have emerged as potential neuroprotective agents for the treatment of NDs [22]. In this context, natural products have been used as structural models in the drug design of ligands against AD, as evidenced by the high number of published studies [23].

CHAPTER 3

Biological Activities of Synthetic Derivatives of Xanthenes: An Update (2016-2020)

Cristina Scarpecci¹ and Sara Consalvi^{1,*}

¹ Department of Chemistry and Technologies of Drug, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy.

Abstract: Natural xanthenes are a class of secondary metabolites widely distributed in nature and with a broad spectrum of biological activities. Their scaffold is amenable to several modifications and has emerged as a “privileged structure” for drug development, representing a very attractive point for medicinal chemistry optimization. A combination of innovative synthetic methodologies and medicinal chemistry studies have provided several xanthone synthetic derivatives for different therapeutic purposes, including cancer, inflammation, Alzheimer’s disease (AD), cardiovascular and infectious diseases. The aim of this chapter is to give an update on the significance of synthetic xanthenes in medicinal chemistry over the last five years (2016-2020), with a focus on their biological activities and structure-activity relationship (SAR).

Keywords: anticancer, drug discovery, natural xanthenes, synthetic xanthenes, SAR analysis.

INTRODUCTION

Xanthenes are a class of *O*-heterocycles symmetrical compounds characterized by a dibenzo- γ -pyrone scaffold (Fig. 1) They can be extracted from different sources [1, 2] (fungi, lichens [3], higher plants [4] and marine organisms [5]) and are widely distributed in nature.

Natural xanthenes have been a rich source for the discovery of novel therapeutic agents for many decades [4, 6]. One of the most representative examples is the polyprenylated xanthone gambogic acid (GA), isolated from *Garcinia hanburyi* (Clusiaceae), which entered clinical trials for the treatment of patients with advanced malignant tumors, including non-small cell lung cancer [7, 8]. Another well-known xanthone is mangosteen, isolated from *Garcinia mangostana* and sold worldwide as a nutritional supplement with anti-oxidant, anti-inflammatory

* Corresponding author Sara Consalvi: Department of Chemistry and Technologies of Drug, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy; E-mail: sara.consalvi@uniroma1.it

and immunostimulating properties [9, 10]. Depending on their structures and position of substituents, natural xanthenes have an incredibly broad spectrum of biological activities [11], such as cytotoxic [12], antiinfective [13], antioxidant [14], cardioprotective [15, 16], anti-inflammatory [17], and antihypertensive [18]. The xanthone scaffold has then emerged as a “privileged structure” for drug development and represents a very attractive point for medicinal chemistry optimization. The xanthone core is amenable to several modifications. However, even though natural sources offer a wide variety of differently substituted xanthenes, the enzymes involved in their biosynthetic pathways could limit their structural diversity. Furthermore, some of them are difficult to obtain through conventional extraction methods and are present only at low concentrations. On the other hand, total synthesis can be a *viable* strategy to easily obtain xanthenes and explore the chemical space and the structure-activity relationship (SAR) around their scaffold [1, 12]. Therefore, combining novel synthetic methodologies and medicinal chemistry optimization is essential to allow the generation of libraries of xanthone synthetic derivatives with enhanced activities, improved safety profiles and acceptable drug-like properties. The importance of xanthone synthetic derivatives has been extensively reviewed [13, 19, 20]. The aim of this chapter is to give an update on the significance of synthetic xanthenes in medicinal chemistry over the last five years (2016-2020), with a focus on their biological activities and SAR.




Fig. (1). General scaffold of xanthenes.

XANTHONE SYNTHETIC DERIVATIVES FOR CANCER THERAPY

The anticancer properties of xanthenes, such as gambogic acid (GA) [21], α -mangostin and 5,6-dimethylxanthenone-4-acetic acid (DMXAA), have been amply studied, and some of them underwent clinical trials [12]. Xanthenes can inhibit tumor growth both *in vitro* and *in vivo*. As shown in Fig. (2), they have several putative mechanisms of action, including apoptosis induction, cell cycle arrest, anti-angiogenesis and anti-metastatic effects, and antioxidant or reactive oxygen species (ROS)-stimulating activity. However, their exact molecular

mechanism is yet to be clarified. The planar scaffold of xanthones, involving a three-ring system, might intercalate DNA and establish non-covalent DNA interactions [22]. Consequently, these promising activities prompted a continuous search for novel xanthone-based anticancer candidates.




Fig. (2). Proposed Anticancer mechanisms for xanthones.

Caged Xanthones (CXs)

Gambogic acid (GA) represents the main bioactive natural product isolated from the gambogin resin secreted by the tropical trees of *Garcinia hanburyi*. GA has a unique prenylated caged xanthone structure and exhibits a wide range of biological activities, including anticancer. Notably, GA inhibits the growth of a broad panel of cancer cell lines *in vitro* and *in vivo* and entered clinical trials in China for the treatment of non-small cell lung, colon, and renal cancers. Several biological targets of GA are described in the literature, including transferrin receptor, nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) pathway, inhibitory kappa B kinase- β (IKK β), heat shock protein 90 (Hsp90) ATPase, p53-Mouse double minute 2 homolog (MDM2) interaction, B-cell lymphoma 2 (bcl-2) pathway [7]. However, as common setbacks of natural products, pharmacokinetic drawbacks such as poor aqueous solubility and a short half-life limited its use as an anticancer drug. Thus, structural modifications were made to improve its drug-like profile and obtain analogues as potential anticancer agents [12]. Recently, Zhang's research group identified SARs around the unique

Combretastatin Derivatives as Tubulin Inhibitors: A Fascinating Journey from Nature to Drug Discovery Strategies

Alessandra Ammazalorso^{1,*} and Trond Vidar Hansen²

¹ Department of Pharmacy, Medicinal Chemistry Unit, G. d'Annunzio University of Chieti-Pescara, via dei Vestini, 66100 Chieti, Italy

² Department of Pharmacy, Section for Pharmaceutical Chemistry, University of Oslo, PO Box 1068 Blindern, N-0316 Oslo, Norway

Abstract: The combretastatins are a family of stilbene phenolic natural products isolated from the bark of the South African bush willow tree *Combretum caffrum*. Since their isolation and structural elucidation, these molecules have attracted a lot of interest due to their potent cytotoxic activity against several human cancer cell lines. Combretastatin A-4, a *cis*-stilbene, is the most potent member of these natural products, has the ability to strongly inhibit tubulin polymerization, resulting in high cytotoxic activity. Indeed, it also displays an additional activity as a potent vascular disrupting agent. This interesting double bioactive profile accounts for the potent antiproliferative and antivascular action in tumors. However, combretastatin A-4, due to the sensitive *cis*-stilbene moiety, is prone to isomerization giving the less bioactive *trans*-isomer and exhibits diminished water solubility. Hence, a wide panel of synthetic derivatives were therefore developed with the aim of overcoming these limitations. The development of prodrugs such as fosbretabulin, ombrabulin and Oxi4503 is representative of successful attempts to overcome pharmacokinetic disadvantages, whereas the most recent approaches aim to develop combretastatin prodrugs able to selectively target tumor site, possessing also theranostic properties. Herein, miscellaneous and the most potent synthetic analogues are presented. In addition, a general outlook on combretastatin derivatives and drug delivery approaches based on innovative nanoformulations is also presented.

Keywords: Anticancer, Combretastatin, Cytotoxic, Colchicine Binding Site, Drug Delivery System, Heterocyclic Derivatives, Natural Compounds, Nanoformulation, Prodrugs, Photoresponsive Hybrid, Stilbene, Structure-activity Relationships, Tubulin Polymerization, Vascular Disrupting Agent.

* Corresponding author Alessandra Ammazalorso: Department of Pharmacy, G. d'Annunzio University, via dei Vestini 31, 66100 Chieti, Italy; E-mail: alessandra.ammazzalorso@unich.it

INTRODUCTION

Natural combretastatins were firstly isolated by Pettit in the 1980s from the bark of *Combretum caffrum* (Eckl. & Zeyh.) Kuntze, an African willow tree [1 - 3]. In the same years, their antimetabolic activity was determined. Extracts from *Combretum caffrum* were traditionally used as a folk medicine for the treatment of scorpion stings, cardiovascular disorders and worm related diseases by the Xhosa tribe in South Africa. From a structural point of view, combretastatins are closely related to stilbenes, representing their *cis*-isomers. These bioactive compounds were classified into four families, namely combretastatin A (CA1 to CA6), combretastatin B (CB1 to CB4), combretastatin C-1 and combretastatin D (D1 to D4). The family A comprises stilbene-based compounds, whereas the family B dihydrostilbenes, phenanthrenes for C and macrocyclic lactones for D. In Fig. 1 the chemical structures of representative members for each family are presented. Overall, their general features are two phenyl rings (one trimethoxy substituted), linked by a *cis*-configured double bond. The mode of action of the combretastatins is closely related to colchicine, sharing with it the ability to bind tubulin and act as polymerization inhibitors. In fact, it was demonstrated that combretastatins bind at the colchicine binding site (CBS) on the β -tubulin in a similar orientation as colchicine. The most prominent representative of this group of compounds is combretastatin A-4 (CA4, 3'-hydroxy-3,4,4',5'-tetramethoxy-*cis*-stilbene), whose principal structural features include a 3,4,5-trimethoxy-substituted phenyl ring (A), a B ring containing C3'-OH and C4'-OCH₃ substituents, and an ethylene bridge providing proper rigidity and spatial orientation of aromatic rings. These structural features were found essential to produce a potent interaction in CBS of tubulin and provide high levels of cytotoxicity [4]. CA4 displays potent antiproliferative effects as an inhibitor of tubulin polymerization, but it induces also marked anti-vascular and anti-angiogenic effects by acting as a vascular disrupting agent (VDA) [5]. The selective disruption of tumor microvessels determines the loss of nutrients, oxygen deprivation and irreversible vascular damage, leading to haemorrhagic necrosis and cell death.

It is interesting to underline that combretastatin A-1 (CA1) and its prodrugs can undergo activation to a cytotoxic *ortho*-quinone intermediate, which interacts with structural elements in proteins and nucleic acids producing oxidative stress through superoxide/hydrogen peroxide production. This chemical behaviour explains the superior antitumor effect played by CA1 compared to CA4, pointing out how little structure differences could affect different pathways into the organisms. Despite the potent cytotoxic, rather simple chemical structure and anti-angiogenic activity exerted by CA4 and CA1, these compounds suffer from some drawbacks, such as the low water solubility and the instability of the *cis*

configuration. Many CA4 and CA1 derivatives were synthesized to overcome the solubility problems, including phosphate prodrugs: CA4 phosphate (fosbretabulin, Zybrestat®) represents a successful derivative, widely studied in many clinical studies alone or in combination with traditional chemotherapeutic agents or with radiotherapy. The isomerization of the *cis* configuration, occurring after *in vivo* administration or in the presence of light, heat, or acidic media, leads to the *trans*-stilbene isomer, significantly less potent at inhibiting tubulin polymerization and diminishing cancer cell growth [6].




Fig. (1). Chemical structures of representative members of four families of combretastatins.

The potent anticancer profile of combretastatins attracted a lot of attention in medicinal chemistry research, stimulating the efforts of researchers to obtain derivatives with improved pharmacokinetic properties and tumor targeting selectivity [7, 8].

INSIGHTS ON MECHANISM OF ACTION OF COMBRETASTATINS

Combretastatins belong to the family of microtubule-binding agents, usually categorized in microtubule-stabilizing (taxanes, epothilones) and microtubule-destabilizing agents (colchicine, vinca alkaloids, combretastatins) when used in

CHAPTER 5

Natural Flavonoid and Chalcone Scaffolds as Leads for Synthetic Antitubercular Agents

Federico Appetecchia¹, Mariangela Biava¹ and Giovanna Poce^{1,*}

¹ Department of Chemistry and Technologies of Drug, Sapienza University of Rome, piazzale A. Moro 5, 00185 Rome, Italy

Abstract: Tuberculosis is a leading cause of mortality and morbidity worldwide, claiming 1.2 million deaths (including 208 000 people with HIV) and 10 million new cases in 2019. Current treatment suffers from significant shortcomings such as length, dosage regimen, toxicity, and resistance development to currently used medicines. The emergence of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis is a major concern in controlling the disease. Therefore, there is an urgent need for new antitubercular drugs that are active against resistant strains, less toxic, and that act upon a different mechanism than the current drugs. Natural products can be a great source for the development of new anti-tubercular agents because of their rich chemical diversity with privileged antimicrobial activity. In this chapter, we focus our attention on flavonoids and chalcone scaffolds as leads for the development of new antitubercular agents.

Keywords: Antimicrobials, Antimycobacterials, Catechins, Chalcones, Coumarin, Epigallocatechin gallate, Flavanones, Flavonoids, Formononetin, Isoflavones, Liquiritigenin, Multi-drug resistant tuberculosis, *Mycobacterium tuberculosis*, Natural products, Quinolines, Secondary metabolites, Tuberculosis.

INTRODUCTION

Tuberculosis (TB) is a leading cause of mortality and morbidity worldwide, claiming 1.2 million deaths (including 208 000 people with HIV) and 10 million new cases in 2019. The annual number of TB deaths is falling globally (between 2015 and 2019 was 14%) less than halfway towards the 2020 milestone of a 35% reduction between 2015 and 2020 [1]. *Mycobacterium tuberculosis* (*Mtb*), the causative agent of TB, can survive within the host, switching between active and latent disease states and evading the immune system defenses. The current frontline TB therapy consists of a co-administration for 2 months of isoniazid

* Corresponding Author Giovanna Poce: Department of Chemistry and Technologies of Drug, Sapienza University of Rome, piazzale A. Moro 5, 00185 Rome, Italy; Tel.: +39 06 49913593; fax: +39 06 499133333; E-mail: giovanna.poce@uniroma1.it

(INH), rifampicin (RIF), ethambutol (EMB), and pyrazinamide (PZA) (Fig. 1) followed by RIF and INH administration for 4 months. This treatment suffers from significant shortcomings such as length, dosage regimen, toxicity, and resistance development to currently used medicines. The emergence of multidrug-resistant TB (MDR-TB), defined as TB that is resistant to INH and RIF, and extensively drug-resistant TB (XDR-TB), classified as being resistant to INH and RIF in addition to any fluoroquinolone and injectable second-line drugs, is a major concern. The World Health Organization (WHO) estimates that in 2018 there were 484 000 new cases with resistance to rifampicin (RIF) (RR-TB), of which 78% had MDR-TB, and 8.5% of MDR-TB cases had XDR-TB [1].




Fig. (1). Chemical structures of the frontline medicines isoniazid (INH), rifampicin (RIF), ethambutol (EMB), and pyrazinamide (PZA).

Therefore, there is an urgent need for new anti-TB drugs active against MDR and XDR strains, less toxic, and that act upon a different mechanism than the current drugs. Except for bedaquiline [2] and pretomanid [3] (Fig. 2) approved by the Food and Drug Administration (FDA) in 2012 and 2019, respectively, and delamanid [4] (Fig. 2), approved by the European Medicines Agency (EMA) in 2014, very few molecules make it through the stringent bottlenecks of TB drug discovery.




Fig. (2). Chemical structures of bedaquiline, pretomanid and delamanid.

Unfortunately, TB drug discovery was completely neglected for a long period of time, and only in the last two decades research all around the globe led to the discovery of new molecules with anti-TB potential [5, 6]. The majority of drugs that are currently being evaluated in clinical trials were identified using phenotypic screening. Indeed, most of the compounds identified by high-throughput screening campaigns and target-based drug design approaches failed to demonstrate activity against *Mtb* in a whole-cell screening assay. Natural products can be a great source for the development of new anti-tubercular agents because of their rich chemical diversity with privileged antimicrobial activity. In this chapter, we will focus our attention on flavonoids and chalcone scaffolds as leads for the development of new antitubercular agents.

FLAVONOIDS

Flavonoids are polyphenolic natural products commonly found in plants and fungi. A significant amount of literature is available that reports the antimycobacterial potential of naturally occurring flavonoids [7].

Epigallocatechin gallate (EGCG, (Fig. 3) the main polyphenol found in green tea, showed several biological activities such as reducing inflammation and oxidative-stress [8] as well as anti-carcinogenic [9] and antimicrobial activity [10 - 12]. Unfortunately, EGCG showed low bioavailability and poor pharmacokinetics because of its rapid biotransformation and degradation after oral or parenteral administration in animal studies and the good *in vitro* results could not be translated into *in vivo* tests [13 - 15]. Banerjee *et al.* prepared triazolyl-flavonoids hybrids by combining the catechin/epicatechin fragment to a 1,4-triazole compounds **1-4**, (Fig. 3) moiety as inhibitors of the FabG4 enzyme of *Mtb*. The role of the different fragments on the activity was evaluated building up structure-activity relationship (SAR) studies by substituting fragments linked to the 1- and 4-positions of the triazole ring with less interacting moieties.

Compounds **1** and **2** showed an inhibition constant (K_i) of 3.97 and 0.88 μM , respectively, against FabG4 and a minimum inhibitory concentration (MIC) of 20 and 5 $\mu\text{g/ml}$ against *M. smegmatis*, proving that both the catechin/epicatechin and the galloyl fragments play a crucial role in the inhibition potency [16].

Gaur *et al.* prepared a series of semi-synthetic derivatives of liquiritigenin LTG, (Fig. 4) a flavanone found in a variety of plants, including *Glycyrrhiza glabra* that showed a MIC of 25 $\mu\text{g/ml}$ against *Mtb* [17]. Plant extracted LTG was derivatized to four analogues: LTG-oxime (**5**), LTG-7,4'-diacetate (**6**), LTG-4'-acetate (**7**) and LTG-7,4'-dibenzoate (**8**) (Fig. 4) Only the oxime **5** and the mono-acetate **7** showed some activity against *Mtb* with a MIC of 25 $\mu\text{g/ml}$, comparable to that of LTG, proving that the hydroxyl group at position 7 is essential for the activity.

CHAPTER 6

In Silico Approaches to Naturally Existing Chalcones and Flavonoids on Mao Inhibitory Action: A Boon to CNS Drug Discovery

Arafa Musa^{1,2}, Della Grace Thomas Parambi³, Mutairah Shaker Alshammari⁴, Rania Bakr³, Mohammed A. Abdelgawad^{3,5}, Dibya Sundar Panda⁶, Manoj Kumar Sachidanandan⁷, Vaishnav Bhaskar⁸, Leena K. Pappachen⁸ and Bijo Mathew^{8,*}

¹ Department of Pharmacognosy, College of Pharmacy, Jouf University, Sakaka, Al Jouf, 72341, Saudi Arabia

² Department of Pharmacognosy, Faculty of Pharmacy, Al-Azhar University, Cairo-11371, Egypt

³ Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Al Jouf, 72341, Saudi Arabia

⁴ Department of Pharmaceutical Analytical Chemistry, Jouf University, Sakaka, Al Jouf, 72341, Saudi Arabia

⁵ Department of Pharmaceutical Organic Chemistry, Beni-Suef University, Beni-Suef, 62514Egypt

⁶ Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka, Al Jouf, 72341, Saudi Arabia

⁷ Department of Oral and maxillofacial surgery and diagnostics, College of Dentistry, Hail University, Hail Province, 2440, Saudi Arabia

⁸ Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Amrita Health Science Campus, Kochi-682 041, India

Abstract: *In silico* studies or computer-aided drug design (CADD) have led to advancement in drug discovery and development of neurodegenerative disorders (NDDs) and neuropsychiatric disorders. CADD is being increasingly used by universities and industries and provides a clear understanding of molecular interactions. Predicting molecular interactions provides relevant information to extract the potential of bioactive compounds. At present, more interest is on natural entities as therapeutic agents with different heterocyclic categories. Various heterocyclic structures are suggested to show MAO (monoamine oxidase) inhibitory activity by CADD and preclinical studies. Among these, chalcones and flavonoids play a major role in MAO inhibitory action because of the phenolic ring. In this chapter, we discuss *in silico* studies of natural chalcones and flavonoids with MAO inhibitory by considering the

* **Corresponding author Bijo Mathew, Associate Professor:** Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Amrita Health Science Campus, Kochi-682 041, India; E-mails: bijomathew@aims.amrita.edu, bijovilaventgu@gmail.com

Simone Carradori (Ed.)

All rights reserved-© 2022 Bentham Science Publishers

complexity of the brain and the multifactorial nature of neurodegenerative disorders. These *in silico* studies prove that phytoconstituents from herbal medicine with therapeutic properties can serve as lead drug molecules for the treatment of NDDs.

Keywords: Apigenin, Chalcone, Flavonoids, *In silico*, Isoflavonoids, Kaempferol, Luteolin, MAO-inhibitor, Neurodegenerative Disorders, Quercetin, Xanthones.

INTRODUCTION

Neurodegenerative disorders are remarked as disorders of the central nervous system often resulting in selective loss of neurons. The research illustrated that deposition of amyloid proteins causes neuronal degeneration. As information pile up to date, no treatments are available for NDDs and are increasing the mortality and morbidity rates in developed countries and the same in developing countries. The reports say that abnormalities in MAOs (monoamine oxidases) lead to various neurological disorders and they have a major role in CNS and peripheral organs. Recent reports also indicate that abnormalities in mitochondria and the enzymes present in the mitochondria, like monoamine oxidases (MAOs), catechol-*O*-methyl transferases, and dopa decarboxylase [1 - 3], lead to NDDs. At this moment, the focus is on the flavin-containing enzyme called monoamine oxidase B (MAO-B), which is present in the outer membrane of mitochondria. MAO-B acts by catalyzing the oxidative deamination of neurotransmitters (dopamine, noradrenaline, and serotonin) and exogenous amines, which are targets for the diseases like Alzheimer's disease (AD), Parkinson's disease (PD), cardiovascular diseases, and also depression [4, 5]. MAO-B is directly involved in damaging neuronal cells by creating reactive oxygen species (ROS), which is the key reason for cell oxidative injury [5]. Identifying the MAO enzymes was a breakthrough in the history of drug discovery.

It is a long-standing tradition to use herbal drugs to treat and cure many diseases, mainly as medicines or sources of unique lead molecules for drug discovery and development of novel medicines [6 - 8]. Reports indicate that half of the top best-selling medicines are natural products, and their sales account for US 16 billion dollars, indicating that herbal medicines can be pre-optimized to be potentially bioactive compounds. Several chemoinformatics analyses also reveal that natural products can act as "drug-like" or "lead-like" and their physicochemical and structural properties can make them leads or drugs. Numerous reports suggest that natural products can act as therapeutic and lead compounds in neurodegenerative diseases [9]. The rational treatment of CNS disorders by natural products is still in its infancy due to the multifactorial nature and complexity of CNS and the complex chemistry and pharmacology of natural compounds.

Several human MAO inhibitors are now used as antianxiety anti-depression agents, whereas human MAO-B inhibitors can be used alone or in combination therapy for Alzheimer's and Parkinson's disease. Phytochemicals have the capacity to alternate the line of treatment in neurodegenerative disease. Herbal compounds have antioxidant properties and the capability to interact with several targets especially signaling pathways, neuroinflammation, and protein folding [10 - 13]. For example, several reports depict that natural compounds containing chalcones and flavonoids exert antioxidant properties directly interacting in Nrf2 pathways by scavenging reactive oxygen species (ROS). It is reported that many antioxidant properties of echinatin, licochalcone, and chalcones are due to proton transfer and electron transfer mechanisms [14], and natural and synthetic analogues like morpholine, naphthoquinone, amphetamine, coumarins, piperine, β -carboline, and caffeine have shown to exhibit appreciable MAO and neuroprotection [15 - 17]. Several synthetic compounds were developed incorporating the basic structure of chalcone and flavonoids as the basic moiety [18 - 23]. This book chapter mainly emphasizes the chalcones and flavonoids containing natural products related to their MAO-B action.

CHALCONES

The name "chalcone" was coined by the scientists Stanislaw Kostanneki and Josef Tambor. Chalcones are open-chain and chemically a three α , β -carbon unsaturated carbonyl system joined to two aromatic rings [24, 25] (Fig. 1) They are also known to be the major precursor in the biosynthesis of some heterocyclic compounds like pyrazolines, benzothiazepine, flavones, and 1,4-diketones.




Fig. (1). Chemical structure of chalcone.

Chalcones are known as a biogenetic precursor of most flavonoids found in fruits (apple, citrus, and tomato), vegetables (potatoes, bean sprouts, and shallots), edible plants like licorice, but do not accumulate much in plants and are abundantly found in Leguminosae, Moraceae, and Asteraceae families. Chalcones are studied for their broad-spectrum activities like antimicrobial, antimicrobials,

Lignins and Lignans – Recent Developments and Trends Regarding their Pharmaceutical Properties

Luc Zongo¹ and Heiko Lange^{2,*}

¹ Department of Pharmacy, University of Saint Dominic of West Africa (USDAO), Doulougou, Burkina Faso

² Department of Environmental and Earth Sciences, University of Milano-Bicocca, Milan, Italy

Abstract: Lignins and lignans as natural polyphenols exhibit a rather broad variety of common physico-chemical features that can be of interest with respect to their use in the pharmaceutical sector. While polyphenol types have antioxidant, antiinflammatory, antibacterial and eventually antiviral activities in common, structural features beyond the polyphenol aspect differ enormously: isolated lignins are oligomers and/or polymers of monolignol C9-building blocks, while lignans are based on dimers thereof. The structural differences caused lignin to be exploited in the pharmaceutical sector mainly as material for the generation of matrices and carrier for drug delivery, while lignans are tested for the suitability as APIs. The chapter gives an overview of this situation, including the biological backgrounds of the two interesting natural polyphenols, isolation and methods for their characterisation.

Keywords: Antioxidant, Anti-Inflammatory, Antibacterial, Antivirus, Antitumor, Carrier, Delivery, Film, Lignin, Lignan, Microcapsules, Nanoparticles, Nanocapsules, Polyphenols, Renewable Resources.

INTRODUCTION

From all the renewable components present in land-based and aqueous biomass, natural polyphenols, namely lignin, lignans and tannins, are respectively important structural materials in the support tissues of vascular plants and valuable products of secondary plant metabolism that have a fundamental role in different stages of plant life, participating mostly in ecological mechanisms of interaction with other organisms and with the surrounding environment, and allowing plants to cope with the adversities. The natural polyphenols offer a wide range of heterogeneous intrinsic reactivities and activities that render them ideal starting oligomeric and polymeric materials for the preparation of functional

* Corresponding author Heiko Lange: Department of Environmental and Earth Sciences, University of Milano-Bicocca, Piazza della Scienza 1, 20126 Milan, Italy; E-mail: heiko.lange@unimib.it

macromolecules and the development of highly value-added materials. Nevertheless, due to the complexity and heterogeneity of their structures, especially in case of lignin and its isolated forms, and a type of historical lack in suitable, *i.e.*, useful detailed structural characterisation and the slow adaption of new structural insights by the wider community, their potential remains somewhat underexploited. Benefitting, however, more than ever simply from sheer necessity to actually find *viable* substitutes for fossil-based materials, valorisation of natural polyphenols in the form of lignin, lignans and tannins is a booming research area, as the development of publications related to the field is indicating.

LIGNIN

Lignin interacts chemically and physically with the other two major components of the plant biomass, *i.e.*, cellulose and hemicelluloses [1]. The tight interplay between these three major plant biopolymers renders the plant cell wall impermeable, confers mechanical strength and rigidity, and overall serves to provide stability to the plants and confers resistance to microbial attacks.

The different functions of lignin in the plant cause its distribution to vary significantly within the different parts of the plant, *i.e.*, among stem, branching points, branches and leaves, and between the different walls of the plant cells themselves [2, 3]. The concentrations of lignin in the middle lamella and the primary cell wall are higher than the lignin concentration in the secondary cell wall. Nonetheless, the majority of the total amount of lignin present in the plant, 75–85%, is located in the secondary wall, due to its considerably large volume. Lignin abundancy is different for every plant species, ranging from ca. 20% in hardwoods, ca. 28% in softwoods and herbaceous angiosperms, to ca. 15% in monocots, accounting overall for 15–35% in average in dry wood [2, 4 - 6]. Unlike the structurally very regular and well-understood cellulose and hemicelluloses, lignin seems to exhibit only random sequences of various interunit bonding motifs [7].

Biosynthesis and Structural Features of Lignins

Lignin formation in cells has been proposed to be a *post-mortem* process in plant cells [8, 9]. The three monolignol building blocks for lignin, *i.e.*, *p*-coumaryl alcohol, coniferyl alcohol, and sinapyl alcohol (Fig. 1) are produced presumably from *l*-tyrosine [10 - 13] or phenylalanine [14, 15] in adjacent living cells and transported into dead cells for lignification of the dead cell in a radical polymerisation process. While being induced by enzymatic activation of the monomers, the polymerisation proceeds most probably without any influence of the dirigent protein.




Fig. (1). Elements of the biosynthesis of lignins. For references, refer to the main text.

CHAPTER 8

Semisynthetic Resveratrol-derived Systems: A Synergism between Nature and Organic Synthesis

Antonella Capperucci¹ and Damiano Tanini^{1,*}

¹ Department of Chemistry Ugo Schiff, University of Florence, Via della Lastruccia 13, I-50019 Sesto Fiorentino, Italy

Abstract: Structural modifications of the resveratrol scaffold are valuable tools in order to develop new derivatives with potential biomedical and pharmacological applications. The investigation of the biological properties of resveratrol-derived semisynthetic systems and the study of their structure-activity relationships are attracting growing interest from medicinal chemists and biologists. In this context, the synthesis of novel resveratrol-derived systems characterised by elevated molecular complexity is highly sought after. Over the past years, a wide variety of resveratrol derivatives have been prepared and studied for their biological properties. Therefore, a number of stilbenoid-related potential anticancer, antioxidant, antiviral, analgesic, and anti-neurodegenerative systems have been investigated. This chapter focuses on recent studies related to the preparation and the study of semisynthetic resveratrol-derived systems.

Keywords: Antioxidants, Anticancer Agents, Functionalization, Organic Synthesis, Prodrugs, Resveratrol, Stilbenoids, Structural Modifications.

INTRODUCTION

Resveratrol is a polyphenol-based natural product which can be isolated from a broad range of plants, where it has been demonstrated to act as phytoalexin [1]. Resveratrol is widely known because of its occurrence in red wine and its implication in the “French paradox” [2]. Owing to its antioxidant activity, resveratrol prevents the oxidation of LDL *in vitro* and reduces the markers of oxidative stress *in vivo* [3]. A number of activities, including antioxidant, anti-inflammatory, anticancer, estrogenic, neuroprotective, anti-atherosclerosis, cardioprotective, anti-diabetic, anti-osteoporosis, anti-obesity, and anti-aging properties, have been described for resveratrol. The abundance and the diversity of resveratrol molecular targets reasonably account for the multiplicity of phar-

* Corresponding author Damiano Tanini: Department of Chemistry Ugo Schiff, University of Florence, Via della Lastruccia 13, I-50019 Sesto Fiorentino, Italy; E-mail: damiano.tanini@unifi.it

macological effects of this stilbenoid. For these reasons, resveratrol and related stilbenoids have been widely studied over the past years. However, the clinical benefits of resveratrol are hampered by unfavourable pharmacokinetic and pharmacodynamics, including poor bioavailability, low aqueous solubility, and chemical instability. In this context, considerable efforts have been devoted to evaluate whether suitable structural modifications could improve or modulate the biological properties of the parent stilbenoid [4, 5]. On the other hand, structural modifications of resveratrol can also be performed in order to improve its metabolic stability and to access new hybrids through the conjugation of two biologically active molecules. Indeed, a number of differently functionalised resveratrol derivatives and resveratrol-based hybrids have been proposed as potential pharmacological tools, exhibiting anticancer [6], antiviral [7], antibacterial [8], analgesic [9] and antioxidant properties [10]. Additionally, resveratrol derivatives have also been studied for their potential role in preventing or treating cardiovascular [11], Alzheimer's, and Parkinson's diseases [12].


This chapter focuses on recent studies on the preparation and the biological properties of semisynthetic resveratrol-derived systems. Only synthetic procedures employing resveratrol as the starting material will be discussed herein. However, several approaches for the preparation of resveratrol-based hybrids rely on the construction of the functionalised resveratrol skeleton through the coupling of suitably decorated and substituted building blocks.

RESVERATROL ETHERS AND RELATED DERIVATIVES


The anticancer activity of a series of resveratrol derivatives, prepared through functionalization of the stilbene double bond and/or protection of phenolic moieties, was reported by Orsini *et al.* [13]. Phenolic groups of resveratrol **1** could be protected as methyl ethers or benzyl ethers to afford compounds **2** and **3** in good yields. Tri-pivaloyl ester and tri-acetyl esters of resveratrol **4** and **5** were, respectively, obtained upon the reaction of resveratrol with pivaloyl chloride or acetyl chloride. Epoxides **6** and **7** were efficiently prepared through the epoxidation of the stilbene double bond of **4** and **5** with *m*-chloroperbenzoic acid (*m*CPBA). Epoxides **6** and **7** could be employed as precursors for a variety of resveratrol derivatives. Ring-opening reaction of **6** with morpholine enabled the formation of regioisomeric amino alcohols **8,9** and **10,11**. Oxidation of these regioisomeric alcohols under Jones conditions was exploited for the synthesis of functionalised ketones **12,13** and **14,15** Scheme (1).

Resveratrol tri-*O*-methyl ether **2** and tri-*O*-benzyl ether **3** were also employed as substrates for the synthesis of enantio-enriched diols (1*S*,2*S*)-**16** and (1*S*,2*S*)-**17** through asymmetric Sharpless dihydroxylation using AD-mix- α . Similarly,

resveratrol-derived enantio-enriched diol (*1R,2R*)-**16** was efficiently prepared from **2** by using AD-mix- β . The enantiomeric purity of both enantiomers of **16** was determined by the application of the Mosher method Scheme (2). Therefore, ^1H and ^{19}F NMR spectra of esters **18** and **19**, were prepared upon the reaction of the aforementioned enantio-enriched diols with (*R*)- α -methoxy, α -trifluoromethyl phenylacetyl chloride, were studied and the optical purity was assessed to be greater than 99%.



Scheme (1). Synthesis of resveratrol derivatives through the reactivity of resveratrol epoxides.



Scheme (2). Synthesis of enantio-enriched resveratrol-derived diols and preparation of corresponding Mosher esters.

Aurone Scaffold and Structural Analogues for the Development of Monoamine Oxidase (MAO) Inhibitors

Paolo Guglielmi¹, Virginia Pontecorvi^{1*} and Atilla Akdemir²

¹ Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy

² Computer-aided Drug Discovery Laboratory, Department of Pharmacology, Bezmialem Vakif University, Fatih, Istanbul 34093, Turkey

Abstract: Continuous efforts in the development of monoamine oxidase inhibitors prompted the search for effective strategies for the design of novel drugs candidate. Thankfully, nature often provides scaffolds useful for the promotion of novel exploitable chemical entities. In this regard, aurones (a class of uncommon flavonoids) and their structural related analogues may play an important role in the development of monoamine oxidase inhibitors. The target prediction of the simplest aurone (2-benzylidenebenzofuran-3(2*H*)-one) clearly suggests that this compound probably affects MAO (monoamine oxidase) enzymes, which is in accordance with the recently reported literature. The current chapter reports the recent discoveries involving aurones and their structurally related analogues as MAO inhibitors, describing detailed structure-activity relationships (SARs) for each subgroup of compounds.

Keywords: Aurones, Homoiso flavonoids, Indanones, MAO inhibitors, Monoamine oxidase, Neurodegenerative diseases, Tetralones.

INTRODUCTION

Human monoamine oxidases (hMAOs) are flavoenzymes that catalyze the oxidative deamination of dietary amines, monoamine neurotransmitters and hormones [1, 2]. The common substrates for MAO include important monoamine neurotransmitters such as dopamine, noradrenaline, adrenaline and serotonin [3]; this leads MAOs to play an important role in behavioral, cognitive, and endocrine regulation [4]. The specificity of MAO for its substrate depends on the concentration, affinity, and turnover rate of the substrate as well as the conc-

* Corresponding author Paolo Guglielmi Ph.D: Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy; E-mail: paolo.guglielmi@uniroma1.it

entration of the enzyme [5]. Two human isoforms have been proposed and discovered, i.e., hMAO-A and hMAO-B. They are characterized by structural homology, active site differences and catalytic efficiency, tissue localization, substrate and inhibitor selectivity [6]. The two isoforms are quite similar, sharing ~70% overall sequence identity [7].

These enzymes are bound to the mitochondrial intermembrane *via* their transmembrane (TM) domains and their catalytic domain is located in the cytosol (Fig. 1). They have subunit molecular weights of 59,700 (hMAO-A) and 58,000 (hMAO-B), consisting of 527 and 520 amino acids, respectively [3]. The (dimeric) holoenzyme has a covalently bound flavin adenine dinucleotide (FAD) cofactor for each subunit, which interacts with Cys406 of hMAO-A or Cys397 of hMAO-B, and an ‘aromatic cage’ which is the site where the amine group of the substrate binds and undergoes oxidation [3, 4, 7].




Fig. (1). The overall 3D structure of human MAO-A in complex with FAD (green CPK) and harmine (turquoise CPK). The cytosolic catalytic domain and the transmembrane (TM) domain that traverses the mitochondrial intermembrane are indicated.

The covalent binding of FAD seems to act as a structural core for the active conformation instead of being required for catalytic activity [5]. Both the isoforms share a substrate binding cavity of ~400 Å³. hMAO-B is also endowed with a hydrophobic cavity of 290 Å³, the “entrance cavity”, which works as a “gate” for the “closed” or “open” conformations [7]. It has been discovered that aromatic and aliphatic residues seem to contribute to substrate selectivity of hMAO-A and hMAO-B [5].

The substrate binding site is located adjacent to the FAD binding site and consists of the conserved residues Tyr69, Tyr197, Phe208, Phe352, Tyr407, Trp441 and Tyr444 (Fig. 2). Also conserved in both isozymes are Phe112, Trp128, Leu176 and Phe177, however, these residues have a significantly different conformation in hMAO-A and hMAO-B (Fig. 2). The amino acids Ala111, Phe173, Ile180, Asn181 and Ile335 in hMAO-A are not conserved and their hMAO-B counterparts are Pro102, Leu164, Leu171, Cys172 and Tyr326. This changes the shape and binding characteristics of the substrate binding sites.




Fig. (2). The active site of hMAO-A in complex with harmine (pdb: 2z5y). The conserved amino acids are indicated in light grey. The amino acids that are different in hMAO-B are indicated in purple (A111, F173, I180, N181 and I335). The amino acids that are conserved but have different conformations are indicated in dark blue (F112, W128, L176 and F177). FAD is indicated in green and only partly shown for clarity reasons. The ligand harmine is indicated in turquoise.




Fig. (3). Structure of chalcones, chromones and coumarins. Structural correlation between flavonoids and aurones.

Coumarins as Carbonic Anhydrase Inhibitors

Claudiu T. Supuran^{1,*}

¹ Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, Pharmaceutical and Nutraceutical Section, University of Florence, via U. Schiff 6, 50019 Sesto Fiorentino, Firenze, Italy

Abstract: Carbonic anhydrases (CAs, EC 4.2.1.1) are metalloenzymes and relevant drug targets with many medicinal chemistry applications. Their classes of inhibitors are in clinical use as diuretics, or drugs for the management of glaucoma, epilepsy, obesity, tumors and infectious diseases. Among the inhibitors discovered so far, coumarins constitute an interesting class. They undergo CA-catalyzed hydrolysis and act as “prodrug inhibitors”, forming 2-hydroxy-cinnamic acids, which bind at the entrance of the enzyme active site, which has a relevant variability of amino acid residues among the different CA isoforms present in mammals, humans included. Coumarins act as isoform-selective CA inhibitors against pharmacologically relevant enzymes, such as the tumor-associated CA IX and XII. Coumarins present as metabolites in many species of bacteria, fungi, plants and ascidians showed relevant CA inhibitory properties and were used as leads for obtaining synthetic derivatives with enhanced enzyme inhibitory action belonging to a variety of classes, such as polysubstituted coumarins on both rings, thiocoumarins, thioxocoumarins, sulfocoumarins, *etc.*

Keywords: Carbonic Anhydrase, Coumarin, Prodrug Inhibitor, Sulfocoumarins, Thioxocoumarins, Tumors.

CARBONIC ANHYDRASE INHIBITORS AND ACTIVATORS

Carbonic anhydrases (CAs, EC 4.2.1.1) are metalloenzymes present in organisms throughout the life kingdoms (Prokaryotes and Eukaryotes), being encoded by eight genetically diverse families [1 - 10]. They catalyze the carbon dioxide hydration to bicarbonate and H⁺ ions. This is a simple reaction but crucial for a variety of processes, both physiologic and pathologic, due to the fact that CO₂ and water, two neutral molecules, generate a weak base, bicarbonate, and a strong acid, and as a consequence, this enzyme plays a key role in acid-base equilibria, pH regulation and metabolism [1, 11 - 15].

* Corresponding author **Claudiu T. Supuran**: Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, Pharmaceutical and Nutraceutical Section, University of Florence, via U. Schiff 6, 50019 Sesto Fiorentino, Firenze, Italy; Tel: +39-055-4573729; Fax: +39-055-4573385; E-mail: claudiu.supuran@unifi.it




Fig. (1). **A.** CA catalytic cycle for the CO₂ hydration/bicarbonate dehydration reaction. **B.** α-CA (hCA II) active site, with the zinc ion and its ligands (His94, 96, and 119) as well as His residues involved in proton shuttling. **C.** α-CA inhibition mechanism by occlusion of the active site entrance [16].

The metal ion is usually zinc(II) coordinated by three amino acid residues and a water molecule/hydroxide ion, acting as a nucleophile in the catalytic cycle – (Fig. 1A) [1 - 9, 16]. The species with zinc hydroxide within the active site is the nucleophilic, catalytically active one, which converts CO₂ bound within the enzyme active site cleft to bicarbonate, originally coordinated to the metal and then released in solution, with the formation of the acidic species, with water coordinated to the zinc. Fig. (1A). This form must lose a proton, a process which is achieved by the so-called proton shuttling residues, usually, His residues, shown in Fig. (1B) [1 - 9, 16]. This is also the rate-limiting step of the catalytic

cycle, but CAs are among the fastest and most effective enzymes known to date [16].

This reaction is crucial for a host of physiologic functions connected to pH regulation processes in all types of organisms and cells [17 - 21]. For this reason, modulating CA activity by using inhibitors and activators, leads to pharmacological applications for the treatment of multiple human diseases. The CA inhibitors (CAIs) are used as diuretics since the '50s [22 - 24], as anti-glaucoma agents [25, 26], antiepileptic drugs [27, 28], antiobesity agents [29, 30], and for the management of metastatic, hypoxic tumors [31 - 36]. The CA activators (CAAs) [37 - 39] started to be used for pharmacological applications more recently, initially for memory therapy [40], or for the modulation of emotional memory, but they may show other applications in areas such as generalised anxiety, post-traumatic stress, phobias, as well as obsessive-compulsive disorders [41, 42].

Among the four CA inhibition mechanisms reported to date for α -CAs [16, 43 - 45], the compounds which occlude the entrance to the active site Fig. (1C). will be discussed. These CAIs bind far away from the catalytic metal ion ($> 10 \text{ \AA}$ away from it), in a region that is rather variable among the many mammalian isoforms, which also favoured the discovery of isoform-selective CAIs [16, 43 - 45]. Coumarins were the first compounds for which this inhibition mechanism has been disclosed by Quinn's group [46], both from the inhibition mechanism and drug design viewpoints. In fact, the discovery of coumarins as CAIs and their particular inhibition mechanism [46, 47] allowed for a rational drug design campaign of a large number of isoform-selective inhibitor classes for many catalytically active human (h) CA isoforms (of the 15 hCA isoforms present in humans, 12 possess catalytic activity, with isoforms VIII, X and XI being devoid of it [1]).

COUMARINS WITH CA INHIBITORY ACTION

Natural Product Coumarins

Among the many natural products that are widespread in organisms all over the phylogenetic tree [48], coumarins play a relevant role in medicinal chemistry due to their multiple pharmacologic applications [49 - 55]. They show a variety of biological activities, such as the anticoagulant effects [55], inhibitors of monoamine oxidase (MAO) [52, 53], antibacterial, antifungal and antiviral actions [51, 54], antioxidant activity [50, 54], antitumor effects [51, 54], as well as anti-inflammatory action [50, 51, 54]. The precise mechanisms of action of coumarins against so many different targets are poorly understood, except for the MAO inhibition and anticoagulant activities [53 - 55]. Coumarins incorporate two

Phenols and Polyphenols as Carbonic Anhydrase Inhibitors

Alessandro Bonardi¹, Claudiu T. Supuran¹ and Alessio Nocentini^{1,*}

¹ Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, Pharmaceutical and Nutraceutical Section, University of Florence, Via U. Schiff 6, 50019 Sesto Fiorentino, Firenze, Italy

Abstract: Thousands of phenolic derivatives have been identified in the plant kingdom, which exert crucial roles in plant physiology. Many such derivatives were shown to produce pharmacological effects in humans which address their use in medicine as antiaging, anti-inflammatory, antioxidant, antidiabetic, and antiproliferative agents among others. Numerous such pharmacological activities are likely to derive from the inhibition of human carbonic anhydrase (CAs, EC 4.2.1.1) isoforms. Phenols, in fact, are able to anchor to the zinc-bound nucleophile present in the enzyme active site, blocking the catalytic action of CAs in humans and/or encoded in various microorganisms. This chapter discusses natural, semisynthetic and synthetic phenol derivatives that exhibited a CA inhibitory action. The discussion over the CA inhibition profiles is categorized as the inhibition of human CAs and inhibition of CAs from microorganisms. Multiple types of inhibition mechanisms by phenolic derivatives are discussed according to X-ray crystallographic resolutions and *in silico* studies.

Keywords: Antitumor, Antibiotic, Anti-infective, Bacteria, Carbonic anhydrase, Enzymology, Fungi, Inhibitor, *In silico*, Phenol, Polyphenol, Protozoa.

PHENOLS AND POLYPHENOLS

Since ancient times, *Homo sapiens* have been using plants and herbal extracts as natural medicines to treat health issues. In modern medicine, the research for natural derivatives as precursors for the development of drugs has spread considerably [1].

More than five thousand phenol and polyphenol derivatives have been identified in plants. They play key roles as structural polymers (*i.e.* lignin), antioxidants, UV screens (*i.e.* flavonoids), signal compounds (*i.e.* flavonoids and salicylic acid),

* Corresponding author Alessio Nocentini: Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, Pharmaceutical and Nutraceutical Section, University of Florence, via U. Schiff 6, 50019 Sesto Fiorentino, Firenze, Italy; E-mail: alessio.nocentini@unifi.it

attractants to accelerate pollination (*i.e.* flavonoids and carotenoids), and defense response chemicals (*i.e.* tannins and phytoalexins), such as coloring for camouflage and defense against herbivores, as well as antibacterials and antifungals [2 - 4].

Numerous phenol derivatives are actively used nowadays in medicine according to demonstrated anti-aging [5], anti-inflammatory [6], antioxidant [7], anti-diabetic (*i.e.* stilbenoids) [8, 9], and antiproliferative activities (*i.e.* flavonoids, phenolic alcohols, lignans, and secoiroides) [10, 11]. Other polyphenol derivatives, such as resveratrol, have been demonstrated to prevent cardiovascular diseases by improving the function of the endothelial tissue, inhibiting platelet aggregation and reducing blood pressure and flogosis [12 - 17].

Carbonic Anhydrases

The superfamily of metalloenzymes carbonic anhydrases (CAs, EC 4.2.1.1) is widely expressed among all life kingdoms. Eight distinct classes are encoded by eight evolutionarily unrelated gene families: α -, β -, γ -, δ -, ζ -, η -, θ - and ι -CAs [18 - 29]. The CAs chiefly catalyze the reversible hydration of carbon dioxide (CO_2) to bicarbonate (HCO_3^-) and proton (H^+). This reaction is physiologically crucial for all living beings as it is involved in respiration, pH and CO_2 homeostasis, transport of $\text{CO}_2/\text{HCO}_3^-$ and a multitude of biosynthetic reactions [18 - 21]. Fifteen α -class CA isoforms are encoded in humans and are implicated in numerous physiological processes such as electrolytes secretion, metabolic reactions (*i.e.* gluconeogenesis, lipogenesis, ureagenesis), bone resorption, and calcification [29 - 39]. An anomalous expression and/or activity of specific human CA isoforms was observed in a multitude of human pathological processes. Hence, many such diseases can be pharmacologically treated with CA inhibitors (CAIs) or activators (CAAs) [18].

Also human pathogens, among which bacteria, protozoa, and fungi, encode for α -, β -, γ - and η -CAs. In fact, CAs are crucial for the parasite virulence, growth or acclimatization in the hosts. The inhibition of these CAs produces growth impairment and defects in the pathogen, being a promising strategy for anti-infective intervention [39, 40].

CA Inhibition Mechanism of Phenol Derivatives

The mechanisms through which CAs are inhibited or activated have been studied for decades and are well-understood processes [18, 19, 41]. To date, four inhibition mechanisms have been discovered and characterized:

1. The zinc-binders, which include inorganic anions, sulfonamides and their bioisosteres (sulfamates, sulfamides), dithiocarbamates (and bioisosteres), hydroxamates, carboxylic acids, phosphates, benzoxaboroles, selenols, phosphoramidates [42 - 50].
2. Compounds that anchor to the zinc-bound water molecule/hydroxide ion, such as phenols, polyamines, sulfocoumarins, and thioxocoumarins [51 - 55].
3. Compounds that occlude the entrance of the active site, that are coumarins and their bioisosteres [56 - 58].
4. Compounds binding out of the active site, that is 2-(benzylsulfonyl)-benzoic acid [42, 59].

The CA inhibition mechanism of phenolic derivatives was described for the first time in 1994 by Nair *et al.* [51], which solved the crystal structure of hCA II in adduct with phenol **1** (Fig. **1A-B**). Successively, Lomelino *et al.* reported an analogous binding mode to hCA II for resorcinol **3** (pdb 4E49) and hydroquinone **4** (pdb 4E3H) (Fig. **1C-D**) [60]. The phenol OH group anchors to the zinc-bound water molecule/hydroxide through an H-bond as a donator, while it receives a second H-bond by the NH backbone of Thr199, a conserved amino acid in the active site of all α -CAs. The benzene ring accommodates within the active site forming hydrophobic interactions with Val121, Val143, Leu198, and Trp209 (Fig. **1**). The *m*-OH group of resorcinol **3** formed a water-bridged H-bond with Gln92. In contrast, two coexisting binding orientations were found for hydroxyquinone **4** within hCA II active site which differ from the orientation of the *p*-OH group. In only one of these, the *p*-OH formed an H-bond with Gln92 side chain NH₂.

Lately, in 2020 a new inhibition mechanism was reported crystallographically by D'Ambrosio *et al.* for catechols [61], which are 1,2-dihydroxybenzene derivatives. Multiple crystallization experiments were conducted on hCA II and chlorogenic acid **49** as CAI produced analogues, *i.e.* the shape of the ligand electron density within the active site was not compatible with **49**, but well matched with its hydrolysis product caffeic acid **42** (Fig. **2**). The authors demonstrated that **49** is hydrolyzed to **42** only in the simultaneous presence of hCA II and the crystallization buffer. Thus, under physiological conditions, this molecule does not act as a suicide inhibitor as coumarins or sulfocoumarins did instead. In detail, **42** is anchored to the enzyme by means of the two OH groups of the catechol which are H-bonded to both the zinc-bound nucleophile and to another water molecule characteristic of α -CAs active site, that is named "deep water" (W_d in Fig. **2**). One of these OH groups is also at H-bond distances from the Thr200 side chain OH and Thr199 amide NH. The organic scaffold of the inhibitor establishes several hydrophobic interactions with residues Val121, Phe131 and Leu198, whereas the carboxylate functionality points towards the protein surface and does not interact with any protein residue.

CHAPTER 12

The Role of Flavonoids and other Selected (Poly) Phenols in Cancer Prevention and Therapy: A Focus on Epigenetics

Melissa D'Ascenzio^{1,*}

¹ D'Arcy Thompson Unit, Biological and Biomedical Sciences Education, School of Life Sciences, University of Dundee, DD1 4HN, Dundee, UK

Abstract: The importance of diet in determining the incidence of chronic illnesses such as diabetes, cardiovascular disorders, neurodegenerative diseases, and cancer has inspired extensive research on the role of individual dietary components in chemoprevention. Flavonoids and (poly)phenols have often been identified as the ideal candidates for these types of studies, as they represent large classes of natural products that are widely available in fruit and vegetables. In this chapter, we will discuss the antiproliferative properties of flavonols, flavanols, flavones, isoflavones, anthocyanins, curcuminoids and resveratrol derivatives, with a particular focus on their ability to interfere with epigenetic processes and modulate gene expression. We will look at the challenges encountered during the optimisation of the pharmacokinetic and pharmacodynamic properties of these natural products and, where possible, we will define structure-activity relationships.

Keywords: Anthocyanins, Anticancer agents, Apigenin, Curcumin, Chemoprevention, Epigallocatechin-3-gallate, Epigenetics, Flavonoids, Flavonols, Flavones, Genistein, Isoflavones, Kaempferol, Polyphenols, Quercetin, Resveratrol.

INTRODUCTION

Chemoprevention and the Epigenetic Mechanisms Associated with Chronic Diseases

According to the latest World Population Prospect published in 2019 by the United Nations, the world's population is predicted to reach 9.7 billion by the year 2050 [1]. Thanks to the progress made by medicine and the implementation of

* **Corresponding author Melissa D'Ascenzio:** D'Arcy Thompson Unit, Biological and Biomedical Sciences Education, School of Life Sciences, University of Dundee, DD1 4HN, Dundee, UK; Tel.: +44 (0) 1382 384682; E-mail: m.dascenzio@dundee.ac.uk

public health measures aimed at improving the quality of care and raising awareness around healthy lifestyles, life expectancy is also expected to increase significantly over the next thirty years. As of today, the fastest-growing age group in terms of percentage of the overall population, is the one represented by persons aged 65 or over. Almost a fifth of the European and Northern American population is constituted by over 65s and this number is predicted to increase until it will reach 25% by 2050 [1]. Unfortunately, an extension in life expectancy does not necessarily translate into an increase in a healthy lifespan. In fact, ageing is one of the major contributing factors to the incidence of chronic diseases such as neurodegenerative disorders, cardiovascular diseases, chronic respiratory diseases, diabetes, obesity, and cancer [2]. In many instances, the decreased mortality associated with these pathologies leads to the development of comorbidities and the overall complication of the patient's clinical picture [3]. In 2002, the growing body of evidence linking dietary and lifestyle habits with the incidence of chronic diseases led the WHO and FAO to conduct a joint expert consultation aimed at producing evidence-based recommendations for the cost-effective prevention and control of chronic diseases [4]. In 2013, these recommendations were incorporated into a Global Action Plan for the prevention of non-communicable diseases (NCDs) and have since been translated into regional and national policies worldwide [5]. While WHO guidelines tend to focus mostly on limiting tobacco and alcohol consumption, reducing salt, sugar, and calorie intake, as well as promoting physical activity, scientific evidence demonstrates that the connection between diet and chronic diseases goes further than that. Recent studies report that the Mediterranean diet and the DASH (Dietary Approaches to Stop Hypertension) diet can slow down cognitive decline [6, 7], while high compliance to a hybrid Mediterranean-DASH diet reduces the incidence of Alzheimer's disease by more than 50% in patients aged 58-98 [8]. In a similar way, the regular consumption of fruits and vegetables has been associated with a significant reduction in the risk of developing several types of cancer, especially those involving the gastrointestinal tract and the respiratory system, but also including breast, bladder, prostate, kidney, cervix, ovary and endometrium cancer [9, 10]. These findings constitute the foundation upon which several dietary components, including micronutrients and phytochemicals, have been studied and adopted in clinical settings as adjuvants in cancer therapy and prevention [11]. This approach takes the name of chemoprevention.

Although there seems to be a general consensus around the fact that most dietary components show neuroprotective and anticancer behaviour thanks to their antioxidant properties, *i.e.* their ability to reduce the oxidative stress caused by the production of reactive oxygen and nitrogen species (ROS & RNS), there is a consolidated body of evidence suggesting that common phytochemicals found in vegetables and fruit can activate stress-response pathways that involve a large

variety of effectors, including transcription factors, protein kinases, and epigenetic modifiers [12, 13].

The dramatic effect that dietary components can have on gene expression through the modulation of epigenetic mechanisms is beautifully captured in the honeybee (*Apis mellifera*) model, where the development of larvae with identical genetic material into queen or worker bees is determined by the food they receive [14]. While the queen bee is fed exclusively with royal jelly, worker bees receive royal jelly only for three days and then move onto a diet made of worker jelly, pollen, and beebread [15]. These dissimilar diets have been proven responsible for the physical and behavioural differences observed in the two honeybee phenotypes. At the cellular level, this phenomenon is caused by changes in DNA methylation levels, particularly at alternative splicing sites [14]. DNA methylation is an archaic mechanism that traces its origin back to bacteria and unicellular organisms and involves transferring a methyl group to the C-5 position of a cytosine base [16]. In humans, methylation usually happens at cytosine-rich regions known as CpG islands, which constitute over two-thirds of mammalian promoters [17]. Although humans do not exhibit the same developmental flexibility as honeybees, DNA methylation of gene promoters has a powerful silencing effect on downstream genes and it plays a fundamental role in embryonic development [18]. Changes in DNA methylation levels at this stage of development can dramatically increase the risk of chronic diseases later in life, as shown by studies conducted on individuals who were prenatally exposed to famine during the Dutch Hunger Winter in 1944-45 [19, 20]. Although these results would be difficult to confirm in humans due to ethical implications, it has been demonstrated in several animal studies that in the uterus and early life exposure to phytochemicals that are known for their ability to inhibit DNA methylation can reduce the incidence of cardiovascular diseases, obesity, and cancer [21 - 24]. In fact, maintaining a balanced DNA methylation status is particularly important to prevent cell transformation, as genome-wide demethylation associated with expression of oncogenes and hypermethylation of CpG islands promoters of onco-suppressor genes constitute a clear hallmark of cancer [17]. However, DNA methylation is not the only epigenetic process that has been found to be dysregulated in cancer development and progression. Epigenetic mechanisms associated with the onset of cancerous phenotypes include post-translational modification (PTM) of histone and non-histone proteins through acetylation, methylation, phosphorylation, ubiquitinylation, citrullination, ribosylation, and sumoylation, as well as non-coding RNA (ncRNA) mediated gene silencing [25]. In this chapter, we will discuss the antiproliferative activity of flavonoids and other selected (poly)phenols of plant origin, with particular reference to their ability to interfere with specific epigenetic mechanisms, such as DNA methylation and the methylation/acetylation of both histone and non-histone proteins.

SUBJECT INDEX

A

- Absorption 3, 13, 14, 15, 16, 45, 82, 134
 low intestinal 3
 lymphatic 82
 oral 45, 134
 Acetate 147, 148, 256
 resveratrol-derived 256
 Acetazolamide 56, 334, 337
 sulfonamide 334
 Acetic anhydride 258
 Acetylation 386, 387, 388, 390, 397, 398, 401,
 404, 408, 415, 422, 428, 439
 Acetyl chloride 250
 Acetylcholinesterase 101, 289
 Acetyl-lysine binding site 404
 AChE 28, 38, 40, 44, 46, 50, 60, 102
 inhibition 28, 38, 40, 50
 inhibition activity 60
 inhibitors 46, 102
 inhibitory properties 44
 AChE enzyme 56, 291
 activities 56
 Acid(s) 5, 7, 8, 11, 16, 31, 82, 95, 120, 121,
 122, 136, 149, 208, 209, 210, 211, 266,
 302, 319, 330, 332, 334, 337, 339, 340,
 349, 350, 352, 363, 428, 455
 acetylsalicylic 210
 ascorbic 208, 209
 bile 31
 caffeic 266, 337
 chalcone ellagic 11
 chlorogenic 332, 337
 coumaric 11
 dihydroguaiaretic 337
 dodecanoic 82
 ellagic 7, 8, 337
 fatty 8, 428
 ferulic 337, 352, 363
 folic 121, 122
 gallic 5, 208, 334
 hydroxy-cinnamic 302
 lactic 211
 lauric 82
 lithospermic 339
 morellic 95
 polyphenol tannic 339, 340
 protocatechuic 334
 rosmarinic 339
 salicylic 330, 334, 349, 350
 suberoylanilide hydroxamic 455
 tannic 208
 trans-hydroxycinnamic 319
 trimethyl quinone propionic 120
 urocanic 136
 Activation 9, 10, 13, 88, 117, 119, 199, 256,
 258, 390, 393, 395, 397, 398, 401, 408,
 410, 413, 414, 415, 422
 adiponectin 13
 enzyme-mediated 119
 induced 408, 422
 ligand-based 415
 mediated prodrug 117
 recurrent oxidative enzyme 199
 transcription 390
 Activators 10, 117, 298, 300, 303, 331, 402,
 454
 myeloperoxidase 117
 Actives 209, 213, 214, 215, 216, 219, 227
 adsorbing 216
 encapsulated 214
 plant-derived 219
 releasing 215
 Activity 2, 3, 10, 12, 13, 16, 30, 34, 35, 37,
 41, 46, 50, 51, 56, 57, 77, 78, 80, 82, 87,
 92, 93, 94, 95, 98, 113, 115, 129, 132,
 147, 148, 149, 151, 159, 161, 162, 165,
 175, 196, 221, 222, 223, 224, 225, 253,
 266, 273, 294, 300, 390, 393, 394, 397,
 402, 413, 422, 428, 429, 440, 458
 acetylase 397
 acetyltransferase 429
 ameliorated 294
 antiangiogenic 394

Simone Carradori (Ed.)

All rights reserved-© 2022 Bentham Science Publishers

Subject Index

anti-angiogenic 113
anti-cancer 3, 223
anti-colorectal cancer 266
anti-estrogenic 253
antifibrotic 222
anti-metastatic 82
antimitotic 113
antimycobacterial 93
anti-mycobacterial 159, 161
anti-neuroinflammatory 46
anti-oxidative 35
anti-trypanosomal 222, 224
antitubulin 129, 132
antiviral 13, 196, 224
apoptotic 458
bactericidal 92, 94
broad-spectrum 175
catalase 51
catalytic 56, 273, 300
deacetylase 428
enzyme 221
epigenetic 402
hemolytic 93, 94, 98
hepatoprotective 222
hypcholesterolemic 222, 223
immunomodulatory 57
immunoregulatory 222, 225
immunostimulant 225
inhibiting proteasome 413
kinase 393
lipoxygenase 2
mitochondria 10
neuroprotective 30, 34, 35, 51, 222, 224
oxidase 390
therapeutic 149
transcriptional 440
vascular disrupting 115
Acute myeloid leukaemia (AML) 117
Acylated umbelliferones 309
ADME properties 387
Adriamycin 254
Adsorption enhancers 4
Advanced drug delivery systems 137
Aerosol flow reactor 212
Aerosol technology 213

Medicinal Chemistry Lessons From Nature, Vol. 1 491

Agents 54, 116, 117, 128, 175, 183, 226, 255,
300, 330, 373, 406, 409, 415, 419, 429,
436, 457, 465, 468
antiangiogenic 116
antianxiety anti-depression 175
antiepileptic 183
anti-glaucoma 300
antiglycating 226
antiobesity 300
antiproliferative 128, 330, 373, 409, 436,
465
anti-tumor 54
antiviral 255
chemopreventive 406, 415, 419, 429, 457,
468
Age-related diseases 9
Aggregation 41, 101, 331
amyloid 41
inhibiting platelet 331
Aglycone caphloretin 7
AKT pathways 266
Aliphatic amines 41, 289
Alkali lignin 211, 212, 217, 218
Alkene bioisostere 124
Alzheimer's disease 27, 73, 101, 174, 189,
226, 289, 385
Amelioration 12, 13
insulin-resistance 13
Amino acids 43, 95, 101, 184, 187, 273, 274,
392, 446
bearing aliphatic 101
Amino alcohols 250, 252
regioisomeric 250
Aminopeptidases 116
Amphiphilic xanthenes 91, 92, 93, 97, 105
cationic 97
Amyloid deposits 28
Anaplastic 116, 117
thyroid cancer 117
thyroid carcinoma 116
Androgen 416, 418
Angelica keiskei 176
Angiogenesis 3, 12, 223, 419, 456, 463, 468
progression 3
Anthocyanidins 4, 6, 13

- Anthocyanin metabolites 16
- Antiaging 30, 221
 - agent 30
 - properties 221
- Anti-angiogenesis agent 135
- Anti-apoptotic factors 394
- Anti-atherosclerosis 249
- Antibacterial 81, 92, 93, 94, 95, 96, 97, 105, 158, 196, 210, 222, 250, 267, 289, 300
 - activity 92, 95, 97, 158, 289
 - agents 94, 97
- Antibiotic properties of lignans 224
- Anticancer 9, 73, 74, 75, 83, 84, 89, 115, 118, 119, 136, 219, 220, 221, 222, 223, 224, 249, 250, 256, 257, 258, 259, 260, 264, 266, 267, 384, 437, 456
 - activity 84, 89, 115, 250, 257, 258, 260, 264, 456
 - agents 115, 118, 249, 384, 437
 - combination therapy 136
 - drugs 75, 83, 119, 223, 266
 - effects 220, 223, 224
 - properties 74, 256, 258, 260
 - stilbenoid-related potential 249
 - therapy 119
- Anticoagulant activities 300
- Antifungal 18, 96, 97, 176, 300, 331
 - activities 96
 - novel membrane-targeting 97
 - xanthone synthetic derivatives 97
- Antihypertensive losartan 17
- Anti-infective intervention 331
- Anti-inflammatory 1, 30, 43, 52, 53, 58, 96, 100, 101, 210, 211, 221, 227, 252, 300
 - action 300
 - activities 30, 43, 52, 53, 58, 96, 100, 101, 211, 221, 252
 - agents 58, 100, 227
 - assays 221
 - effects 1, 100, 210
- Antimalarial agents 99
- Antimicrobial 30, 56, 91, 92, 147, 219, 222, 224
 - activities 30, 92, 147, 222, 224
 - agents 56, 219, 224
 - peptides 91
- Anti-neurodegenerative effects 17
- Anti-osteoporosis 249
- Antioxidant 2, 38, 41, 103, 175, 185, 250, 255, 263, 267, 385, 431
 - properties 2, 38, 41, 103, 175, 185, 250, 255, 263, 267, 385
 - reactions 431
- Antioxidant activity 8, 18, 30, 35, 40, 43, 46, 49, 52, 56, 59, 60, 102, 103, 220, 224, 368, 454
 - agents 102, 103
 - effects 18, 43, 60, 368
 - enzymes 8, 18, 52, 454
- Antioxidant enzymes 10, 89
 - catalase 89
 - transcription 10
- Antiproliferative 113, 129, 130, 131, 132, 393, 394, 395, 401, 431, 435, 436, 438, 439, 441, 446, 459, 460, 461, 462, 464, 465
 - activity 129, 131, 132, 401, 435, 436, 438, 439, 441, 459, 460, 461, 462, 464, 465
 - effect 113, 130, 393, 394, 395, 431, 446
- Antiradical activity 9
- Anti-tubercular activity 154, 162
- Antitumor 1, 2, 76, 81, 105, 120, 124, 131, 196, 257, 300, 330, 408, 463
 - activity 76, 105, 120, 124, 257, 408
 - effects 2, 131, 300
 - activity 463
- Antiviral properties of lignans 224
- Apoptosis 51, 81, 82, 83, 88, 89, 226, 394, 395, 396, 397, 398, 401, 408, 413, 420, 438, 439
 - curcumin-induced 438
 - delphinidin-induced 420
 - homeostasis 83
 - induced 226, 395
 - inhibiting 397
 - stimulated ROS-mediated 89
- Applications 1, 2, 3, 10, 17, 19, 134, 137, 206, 211, 213, 214, 216, 219
 - antimicrobial 219
 - biomedical 211
 - dermatologic 3

Subject Index

Arginine 97, 388, 389, 391
 demethylases 391
 methylation 391
 methyltransferase 389
 symmetrical dimethyl 389
Aromatase 461
 inhibition and antiproliferative activity 461
Aromatic hydrocarbon receptor 456
Artificial membrane permeability assay 280
Astrocytes 46, 52
Atherosclerosis 412
ATP binding 15, 17
 cassette (ABC) 15
 sites 17
ATP viability assay 94
ATR technique 206
Autoradiography 151

B

Bacillus cereus 93
Bacteria 93, 225, 298, 321, 330, 331, 360,
 373, 386
 anti-pathogenic 225
 pathogenic 321
Balance, soil carbon 214
Benzothiazole derivatives 132
Benzylidene 181, 279, 280, 285, 291, 346
Binding site 104, 185, 398, 403, 404, 427, 435
 allosteric 104
 cytosine 427
Bioactive trans-isomer 112
Biological 1, 55, 60, 162, 202, 249, 250, 253,
 437
 assays 162
 properties 1, 55, 60, 202, 249, 250, 253,
 437
Biosynthesis 86, 151, 175, 198, 203, 204
 anabolic 86
 mycolic acid 151
 and structural features of lignans 203
Bovine serum albumin (BSA) 434, 435
Brain tumour 224
Breast 78, 127, 398

Medicinal Chemistry Lessons From Nature, Vol. 1 493

 adenocarcinoma 398
 carcinoma 78, 127
Breast cancer 80, 82, 222, 223, 413, 414, 415,
 416, 426, 452, 455, 456
 inflammatory 80
Burkitt lymphoma 439

C

Caco-2 assays 401
Caenorhabditis elegans 221
Caged xanthenes (CXs) 75, 78, 79, 80, 95
CA inhibitors 298, 300, 302, 331
 isoform-selective 298
Cancer 8, 10, 29, 32, 74, 86, 91, 116, 118,
 127, 223, 258, 384, 385, 386, 392, 393,
 396, 397, 398, 402, 406, 407, 408, 411,
 412, 417, 418, 419, 424, 462, 467, 468
 bladder 396, 397
 chemoprevention 424
 colon 118, 127, 398, 419, 462, 467
 endometrium 385
 genitourinary 393
 glioblastoma 91
 hepatocellular 86
 oestrogen-responsive 408
 ovarian 116
 pancreatic 258
 therapy 10, 74, 385, 392, 397, 402, 468
Candida albicans 360, 361
Carbohydrate-lignan conjugates (CLCs) 222,
 226, 227
Carbon dioxide hydration 298
Carboxylic acids 259, 315, 332, 400, 401, 443
 heteroaromatic 259
Carcinogenesis 220, 224
Carcinogen metabolizing enzymes 252, 253
Catechol-O-methyl transferase (COMT) 16,
 174, 415, 417, 426
Cell 51, 388, 402, 429, 464
 apoptosis 464
 lymphoma 429
 metabolism 51, 388, 402
Cell cycle 84, 413, 438, 439, 452

- arrest, curcumin-induced 438
- Cell death 92, 93, 113, 225, 393, 395, 454, 439
 - apoptotic 225
 - cardiomyocytes 454
 - kaempferol-induced 395
- Cellular 125, 136
 - assays 125
 - proliferation inhibition 136
- Cerebellar granule neurons (CGNs) 46
- Cervical cancer 130, 258, 259, 260, 263, 416, 463
 - epithelial 263
 - HeLa cells 259, 260
- Chains 38, 77, 95, 285
 - aminoacidic 95
- Chalcones 9, 149, 150, 151, 152, 153, 154, 158, 159, 161, 165, 166, 175, 176, 189, 277
 - ferrocene-based 165
 - fluoro-substituted 150
 - halogenated 150
 - pyrazoline-based 152, 153
- Chelating activity 103
- Chemical structure 177, 179, 180, 186, 342, 343
 - of genistein 186
 - of polyphenols 342, 343
 - of quercetin 179
 - of resveratrol 177
 - of xanthone 180
- Chemistry, phosphoramidite 264
- Chemoinformatics analyses 174
- Chemotherapeutic agents 135, 137
- Chemotherapy 120, 137
- ChEs 39, 40, 41
 - inhibition activity 40
- Cholinergic transmission 28
- Cholinesterase 288
- Chromatin immunoprecipitation assays 440
- Chromodomains 390
- Chronic 8, 220, 221, 222, 225, 385, 386
 - diseases 8, 220, 385, 386
 - hepatitis B (CHB) 221, 222, 225
- CNS 176, 189, 467
 - cancer 467
 - disorders 176, 189
- Cofactor, enzymatic regulatory 34
- Cognitive dysfunctions 13
- Colchicine binding site (CBS) 112, 113, 115, 123, 127, 460
- Colon tumor 18
- Colorectal cancer 408, 467
- Colorimetric assay 55
- Column chromatography 178
- Computational modeling in human mono oxidase 189
- Computer-aided drug design (CADD) 163, 173
- COMT transcription 415
- Conjugates 17, 31, 101, 134, 135, 222, 226, 258, 261, 262, 263, 315, 317
 - carbohydrate-lignan 222, 226
 - glucuronide 17
- Consumption 16, 18, 385, 413, 419, 454
 - alcohol 385
 - tobacco 454
- Coronavirus disease 13
- Coumarin(s) 302, 318, 462
 - hybrids 462
 - hydrolyzed 302, 318
 - scaffold 318, 462
- COX-2 gene silencing 398
- Cryptococcus neoformans 360, 361
- Curcuma longa* 437, 438
- Cyclin-dependent kinase inhibitor genes 440
- Cyclooxygenase 2, 28, 221, 393
- Cytokines 9, 12, 57, 413, 429
 - proinflammatory 9, 12, 429
- Cytosolic isoforms 311, 349, 402
- Cytotoxic 86, 89, 124, 125, 127, 129, 209, 222, 399, 430, 442, 443, 446, 450
 - activity 86, 124, 127, 129, 209, 222, 399, 430, 442, 443, 446
 - effects 89, 125, 450
- Cytotoxicity 50, 94, 95, 119, 120, 121, 123, 124, 125, 255, 258, 259, 260, 447, 449, 450
 - glutamate-induced 50
- Cytotoxic properties 122, 401

D

Damages 2, 12, 27, 51, 113, 275, 368, 393, 402, 419, 454
irreversible vascular 113
joint 12
lipid 454
nerve 12
oxidative 51, 275, 393, 402
oxidative cell 419
Defense 225, 331
restoring antioxidant 225
Degeneration 12, 28, 174
neuronal 174
Degradation 4, 135, 147, 225, 402, 416, 428
protease 402
Degradation products 206, 209
enzymatic 209
Dehydrogenation 150, 202
polymers 202
Delivery 119, 122, 132, 134, 135, 196, 213
oral 134
strategies 119, 132
vehicle 213
Delivery systems 31, 135, 400
nanoparticle 31
novel tumor-selective drug 135
Delphinidin skin 422
Demethylation 19, 391, 416, 428, 440, 452, 467
aspecific DNA 428
microwave-assisted 19
Dendron-polymer-dendron (DPD) 135
Dengue virus 13
Derivatives 1, 15, 95, 147, 349, 356, 387, 441, 462
phenolic acid 15
semisynthetic 1, 95, 349, 356
semi-synthetic 1, 147, 387
styrylcoumarin 462
tetrahydrocurcumin 441
Detoxification 119, 224
enzymes 224
Diabetes mellitus 103

non-insulin-dependent 103
Dietary supplements 2
Diets, rich 408
Dihydrochalcones 178, 276
Dihydrocurcumin 437
Dihydroxyxanthones 85, 86
Diseases 2, 8, 10, 12, 28, 29, 30, 32, 54, 56, 59, 174, 176, 187, 220, 222, 223, 226, 255, 331, 385, 386, 392, 454
autoimmune 12
cardiac 10
cardiovascular 8, 174, 176, 220, 222, 226, 255, 331, 385, 386, 454
chronic respiratory 385
degenerative 56
lateral sclerosis 28
malignant 223
neurological 187, 226
oncological 392
oxidative stress-relative 2
rheumatic organ 12
Disorders 30, 56, 100, 113, 173, 174, 182, 220, 226, 384
cardiovascular 113, 384
gastrointestinal 182
metabolic 100
neurological 174, 226
neuropsychiatric 173
DNA damage 2, 13, 387, 392, 393, 415
oxidative 415
replication 387
/RNA polymerase 13
synthesis 2
DNA hypomethylation 426, 440
curcumin-induced 440
DNA methylation 386, 414, 415, 421, 426, 438
inhibiting 438
DNMT 398, 415
inhibitor 415
isoforms 398
Dopaminergic neurons 12, 30
protecting 30
Downregulating hydroxyproline 225
Downstream signalling 394

Drug(s) 8, 10, 12, 17, 28, 29, 73, 99, 100, 101, 117, 132, 133, 134, 135, 136, 145, 146, 147, 149, 161, 174, 215, 264, 300, 393, 415

anti-cancer 393
antiepileptic 300
anti-inflammatory 100, 264
antioestrogen 415
antivascular 134
 degradation 132
herbal 174
hydrophilic 136
lipophilic 215
mucoprotective 149
novel anti-TB 161
orphan 117
toxic 12

Drug delivery 120, 133, 134, 196, 215, 226
 tumor-selective 134
 tumor-targeted 120

Drug delivery systems 112, 117, 132, 133, 134

 liposome-based 133

Dysfunction 12, 28, 37, 100
 mitochondrial 12, 28, 37

Dysmetabolic syndrome 13

E

Effects 46, 55, 74, 113, 119, 136, 220, 222, 223, 225, 250, 300, 393, 401, 414, 415

antiangiogenic 136
anti-angiogenic 113, 393
anticoagulant 300
anti-estrogenic 223
antifibrotic 225
anti-metastatic 74
anti-oxidant 55
apoptotic 220, 222
biphasic 414
chemotherapeutic 415
immunomodulatory 220
macological 250
neurotoxic 46

 proapoptotic 401
 radiosensitization 119

EGF receptor kinase 398

Electron 46, 77

 cloud density 77

 density 46

Electronic factors 151

Electrospinning 211

Electrostatic adsorption 216

Enterohepatic recirculation 16

Environmental sensor 414

Enzymatic 15, 429

 conversion 429

 protein lactase phlorizin hydrolase 15

Enzyme(s) 39, 40, 56, 57, 103, 185, 216, 273, 298, 300, 302, 303, 305, 308, 321, 370, 388, 393, 395, 402, 410, 430, 441

 aldoketoreductase 441

 catalytic activity 370

 effective 300

 epigenetic 395

 metabolic 393

 restriction 430

 tumor-associated 305, 308

Epicatechin 5, 16, 341, 424, 426, 435

Epidermal growth factors 413

Epigallocatechins 16, 424

Erectile dysfunctions 19

Esterase assay 355, 358, 359

Esterases 258, 436

Esterification 104, 119, 256, 260, 267, 351

Expression 89, 90, 221, 331, 386, 392, 393, 394, 395, 396, 397, 410, 413, 414, 415, 422, 423, 424, 428, 440, 463, 465

 acetylation activity 422, 423, 424

 anomalous 331

 of oncogenes 386, 392, 463

F

FAD 28, 181

 containing enzymes 28

 in human monoamine 181

Fenton reaction 10, 103, 275

Subject Index

Fibres 129, 212, 227
 actin stress 129
Fibrils 28
 amyloid 28
Fibroblast growth factor (FGF) 393
Flavanols catechin 13, 341
Flavanones 4, 6, 9, 12, 13, 145, 147, 184, 276,
 341, 392
 naringenin 341
 naringin 13
Flavin adenine dinucleotide (FAD) 177, 181,
 188, 189, 273, 274, 288
Flavoenzymes 272
Flavones 4, 5, 9, 11, 13, 372, 384, 392, 395,
 407, 408, 409, 411
 apigenin 409
Flavonoid(s) 10, 14, 15, 16, 17, 404
 activity 10
 catecholic 16
 metabolism 14, 15, 17
 poly-acetylated 404
Flavonone glucosides 9
Flavonoid derivatives 402, 404
 methylated 404
Fluorescence 121, 206
 interfering natural 206
Fluorescence assay 43, 151
 ligand binding tryptophan 151
Fluorescent probe monochlorobimane 45
Fluorimetric assay 33
Flux, transcellular 17
Food and drug administration (FDA) 47, 48,
 117, 146
Fosbretabulin 112, 114, 115, 116, 117
 combinations of 116
Fourier-transform infrared spectroscopy 206
FRAP assays 56
Free radical(s) 29, 30, 179, 221, 368
 oxidative 29
 scavenger 221
Functions 1, 5, 9, 27, 28, 47, 99, 165, 179,
 197, 199, 210, 331, 370, 372
 biological 165
 carboxylic 370
 hydroxylic 1

Medicinal Chemistry Lessons From Nature, Vol. 1 497

 immune 28
 ketonic 5
Fungal 30, 177, 360
 infections 30
Fungal metabolite 339, 362
 endophytic 339
Furan heterocycle 307

G

GADPH inactivation 177
Gambogic acid (GA) 73, 74, 75, 76, 79, 81,
 90, 99
 polyprenylated xanthone 73
Gardenia ternifolia 187
Gastrointestinal ulceration 264
Gatifloxacin 218
Gel permeation 207
 chromatographic methods 207
 chromatography (GPC) 207
Gene(s) 9, 10, 254, 260, 386, 388, 394, 398,
 409, 410, 413, 414, 416, 420, 422, 423,
 424, 427, 428, 440, 454, 455
 expression 9, 10, 260, 386, 409, 410, 440,
 454
 downstream 386
 lipogenic 10
 methylation-silenced 427, 440
 onco-suppressor 386, 394, 410
 proinflammatory 398
 promoters 386, 398, 414
 pro-metastatic 428
 regulation 414
 silencing 398, 440
 suppressing 414
 transcription 388
 tumour suppressor 414, 455
Genetic factors 27
Genistein 7, 11, 13, 186, 187, 412, 413, 414,
 415, 416, 417, 418, 419
 breast 417, 418
 cervical 418
 isoflavone 186
 oesophageal 419

- prostate 418, 419
 - Genome 401, 408, 416
 - wide changes 408
 - Gentiana lutea* 178
 - Ginkgo biloba* 395
 - Glioblastoma 91, 256
 - Glucocorticoids 100
 - Gluconeogenesis 331
 - Glucose 10, 52, 104, 314
 - hepatic 104
 - Glucosylated dihydrochalcone 7
 - Glucuronate 30
 - Glucuronidation 15, 16
 - enzymes 16
 - Glucuronide 441
 - Glutathione 89, 117, 118, 134, 454
 - peroxidase 89
 - reductase (GR) 454
 - Glycolysis 10, 86
 - Glycosides 5, 15, 354
 - acetylated 354
 - flavonoid 15
 - Glycosylated coumarins 313
 - Glycosylation 4, 267, 392
 - Glycosylcoumarins 314
 - Green tea polyphenols (GTP) 428
 - Growth 77, 78, 162, 163, 263, 364
 - inhibition 77, 162, 163, 364
 - inhibitory activities 78, 263
 - GSH depletion 262
 - Gymnosperms 199
- H**
- Haematopoiesis 414
 - Haemorrhagic necrosis 113
 - HDAC inhibitory activity 415, 444, 445, 446
 - Heart 10, 17, 220, 222, 223, 275
 - coronary 10
 - disease 220, 222, 223
 - Heck reaction 149
 - HeLa 130, 132, 258, 260, 263, 421, 423, 440, 443, 445, 448, 450, 460, 463, 466
 - human cervix carcinoma 130
 - Heme oxygenase 454
 - Hemicelluloses 197
 - Hemolysis 93, 94, 98
 - Hepatic stellate cell (HSCs) 225, 226
 - Hepatitis 13
 - Hepatocellular carcinoma 86, 136, 402
 - Hepatoprotective 224
 - Hepatoprotective effects 225
 - of lignans 225
 - Herbaceous angiosperms 197
 - Herbs 179, 186, 395, 408
 - medicinal 186
 - Hesperetin 6, 11, 13, 17
 - lipophilic 17
 - Hesperidin 6, 11, 341
 - glycoside 6
 - Heteroaromatic nuclei 275
 - Heteroaromatics 124
 - Heterocycles 38, 50, 60, 90, 104, 130, 166, 284, 292, 468
 - isosteric 468
 - nitrogen-based 166
 - Heterogenicity 8
 - Histone 378, 387, 388, 390, 398, 399, 402, 407, 408, 411, 416, 417, 418, 419, 420, 422, 423, 424, 439, 455
 - deacetylases (HDACs) 387, 388, 398, 399, 402, 407, 408, 411, 416, 417, 418, 419, 420, 423, 439
 - demethylases 390
 - hyperacetylation 455
 - methylation 388
 - proteins 387, 388, 422, 423, 424
 - Histone acetyl 387, 388, 417, 429, 439, 452
 - transferases 387, 388, 429
 - transferases (HATs) 387, 388, 417, 429, 439, 452
 - Histone acetyltransferase 397, 429, 439
 - activity 397, 439
 - inhibitor 429
 - Holoenzyme 273
 - Homogeneities 211
 - Homioflavonoids 180, 181, 272, 277, 289, 290, 292, 293
 - derivatives 289

Subject Index

multifunctional 290, 292
synthetic 289
Human umbilical vein endothelial cells
(HUVECs) 135, 136
Humulus lupulus 19
Huntington's diseases 12
Hyacinthaceae 180, 289
Hybrid molecules 156, 158
 chalcone-based 156
Hybrids 27, 47, 263, 267
 piperazinyl pyrimidine 47
 resveratrol-derived 263, 267
 stilbene-based 27
Hydrochloride 77, 259, 261
 carbodiimide 259, 261
Hydrogenation 18
Hydrogen peroxide 35, 52, 55, 275
Hydrolysis 14, 16, 91, 103, 258, 303
 esterase 91
Hydrolytic enzymes 103
Hydrophobicity 92
Hydrophobic nature 293
Hydroxyl radicals scavenging assays 103
Hypericum hircinum 179
Hyperuricemia 12
Hypoacetylation 429

I

Imidazolium halides 462
Immobilisation 216, 218
Immune system defenses 145
Immunoliposomes 134
Immunomodulators 58
Induced repression 415
Inducible nitric oxide synthase enzymes 10
Infections 12, 94, 151, 177, 321
 bacterial 177
 urinary tract 12
Inflammation 9, 10, 12, 28, 51, 53, 73, 105,
 147, 398, 437, 468
 chronic 398
 reducing 147
Inflammatory 10, 80, 81

Medicinal Chemistry Lessons From Nature, Vol. 1 499

breast cancer (IBC) 80, 81
 cascade 10
Inflammatory response 30, 422
Inhibiting tubulin polymerization 114, 123
Inhibition 42, 43, 50, 286, 456
 activity 42, 43, 50
 impairment 286
 synergistic 456
Inhibition mechanisms 300, 314, 317, 321,
 330, 331
 enzymatic 321
Inhibitors 113, 118, 128, 226, 291, 321, 402,
 404, 439
 acetylcholinesterase 226
 angiogenesis 128
 bromodomain 402, 404
 cholinesterases 291
 coumarin 321
 deacetylase 439
 polymerization 113, 118
Inhibitory action 157, 176, 181, 298, 351
 enhanced enzyme 298
Inhibitory activity 48, 50, 104, 278, 279, 282,
 283, 284, 285, 287, 289, 291, 293, 302,
 349, 363, 461
 elicited nanomolar 283
 quinone reductase 461
 synergic 104
Instability 113, 116, 452, 460
 metabolic 460
Interactions 154, 176, 189, 387, 404
 enzyme-inhibitor 176
 histones-DNA 387
 lipophilic 404
 protein 154
 protein-ligand 189
Intestine 14, 15, 16, 428, 467
Intracellular 28, 29, 93, 95, 159
 bacilli 159
 components leakage 93
 invasion 95
 neurofibrillary tangles 28
 protein aggregates 29
Invasive prostatic adenocarcinoma 455
Iron chelator 48

- Irradiation 120, 134, 206
sources 206
- Isocombretastatin derivatives 124
- Isocombretastatins 123
- Isoenzymes 28
- Isoflavones 7, 9, 13, 384, 392, 395, 412, 413, 414, 416, 417
- Isoflavones biochanin 341
- Isoflavonoids 5, 7, 174, 275
- Isoforms 317, 387, 388, 391
enzymatic 387
nuclear 388
purified 391
transmembrane 317
- Isoforms Hca 305, 308, 310, 317, 319, 337, 355
cytosolic 305, 308, 310, 317, 319
inhibited 355
mitochondrial 337
- Isolated biopolymer 199
- Isomeric 131, 308, 309
phenolic ketone pairs 309
- Isoprenyl, hydrated 307
- J**
- Jumonji histone demethylases 406
- K**
- Kaempferol Leukemia 407
- Kinases 10, 12, 413, 438
monophosphate-activated protein 10
- KRAS-mediated signalling pathway 266
- L**
- Lactones, macrocyclic 113
- Laser light scattering detectors 208
- Leguminosae 7, 175
- Leucoanthocyanins 5
- Leukemia 224, 439, 448, 466, 467
lymphocytic 224
- Leukemia cells 395, 450, 466
acute lymphoblastic 395
acute myeloid 466
- Lewis lung carcinoma 135
- Lewy neurites 29
- Lignan biosynthesis 204, 205
- Lignans 220, 221
anti-inflammatory properties of 221
dietary 220
- Lignins 196, 197, 199, 200, 202, 203, 204, 206, 207, 208, 209, 210, 211, 212, 213, 214, 216, 217, 218, 219, 227, 228
acetic acid 216, 217
biopolymer 209
carbohydrate complexes (LCCs) 210
fractionation 202, 227
fractions 227
hydrolyzable 217, 218
metal frameworks 213
microcapsules 213, 216, 217, 218
nanotubes 213
polymeric 219
synthetic 202
- Lineweaver-Burk analysis 405
- Lipase 216, 217
- Lipid 10, 134
oxidation 10
stabilised oil nanodroplets 134
- Lipogenesis 331
- Liperoxidase 12
- Lipopolysaccharide 46
- Liposomes 3, 31, 91, 132, 134, 135, 136
- Lipoxygenases 28, 393
- Lithium chloride 19
- Liver carcinoma 263
- Liver fibrosis 225, 226
attenuated ConA-induced 225
progression 225
- Liver protection 225, 226
effect 226
- Low-density lipoprotein (LDL) 249, 402, 454
inhibiting 454
- LPS 30, 47, 253
activated microglia 47
induced neurotoxicity 30

Subject Index

mediated iNOS induction 253
Luciferase 161, 397, 450
 activity essay 450
 assay 397
 reporter mycobacteriophages 161
Lung 130, 132, 224, 258, 262, 462
 adenocarcinoma 132, 258
 carcinoma 130, 462
 non-small-cell 262
 tumours 224
Lymphoma 452
Lymphovascular invasion 80
Lysine 387, 388, 389, 390, 391, 392, 397, 404,
 416, 429, 440, 468
 acetylated 387
 demethylases 390, 391, 404, 416
 demethylases 468
 methylated 391, 440

M

Magnolia officinalis 225
Malignancies 129, 393, 412
 haematological 393
 oestrogen-responsive 412
Malignant phenotype 456
MAO 176, 187, 275
 inhibitory activity 176, 187
 mediated oxidative stress 275
MAPK 48, 419
 pathways 48
 signalling 419
Mass spectrometry methods 208
Mateon therapeutics 117
Medicines 2, 174, 225, 330
 herbal 2, 174, 225
 natural 330
Melanoma cells 124, 135, 440
Melibiopyranose 314
Memory 30, 182, 300
 emotional 300
Menopausal symptoms 13, 222, 223
Metabolic stability 94, 119, 250, 259, 406,
 468

Medicinal Chemistry Lessons From Nature, Vol. 1 501

Metabolism 1, 9, 10, 14, 16, 18, 51, 298, 424,
 426, 467
Metabolites 13, 14, 15, 16, 17, 222, 226, 298,
 356, 425, 437
 aglycone 15
 bacterial 226
 flavonoid 14
 glucuronidated 17
 natural phenolic fungal 356
Metal 38, 42, 59, 102
 chelators 38, 102
 dyshomeostasis 59
 ion chelator 42
Metalloenzymes 298, 331, 391
 carbonic anhydrases 331
Metastases, solid tumor 82
Methicillin resistant *Staphylococcus aureus*
 (MRSA) 93
Methods 152, 206, 210, 263
 biorefinery 210
 mixed anhydride 263
 spectroscopy-based analysis 206
 synthetic 152
Methylation reactions 15, 265, 426
Methyltransferases 16, 398, 427
Metronidazole-coumarin conjugates 312
Micromolar inhibitors 293, 312, 353
Microplate alamar blue assay (MABA) 154,
 155, 156, 160, 162, 164, 165
Minimum inhibitory concentration (MIC) 97,
 98, 147, 151, 152, 153, 154, 155, 156,
 157, 158, 160, 161, 162, 164
Mitochondrial 56, 179
 carbonic anhydrase 56
 enzymes 179
Mitogen-activated protein (MAP) 12
Modifications 386, 387, 388, 390, 391
 epigenetic 390
 post-translational 386, 387, 388, 390, 391
 reversible 391
Modulating histone 428, 455
 acetylation 455
 deacetylase activity 428
Monoamine 176, 181, 272, 277, 300
 oxidase inhibitors 272, 277, 300

oxidases, human 176, 181, 272
Monodentate chelation 444
Monomers 16, 197, 199, 371, 373
 flavonoid 16
Monomers lignin 209
Monooxygenases 15
MTT assay 459
Mukaiyama-aldol reaction 149
Multidrug resistance 12, 15, 85
 associated protein 85
 proteins 15
Multifactorial nature 174
Multifunctional antioxidant 44
Multiple 183, 402
 myeloma 402
 sclerosis 183
Murine 129, 161, 336, 339, 341, 345, 353,
 355, 356
 transformed 129
Mutagenesis 2
Mycobacterial 93, 94, 150
 biofilms 94
 enzyme 150
 membranes 93
 tyrosine-phosphatases 150
Mycobacterium tuberculosis 93, 145, 360,
 361, 363
Myelodysplastic syndromes 117
Myofibroblasts 262

N

NADPH quinone oxidoreductase 119
Nanoformulations 112
Nanohydrogels 136
Natamycin 98
Natural 34, 249, 300, 301, 303, 304, 306, 307,
 308
 antioxidant agent 34
 product coumarins (NPCs) 300, 301, 303,
 304, 306, 307, 308
 products, polyphenol-based 249
NDs 28, 60
 pathophysiology 28

 therapy 60
Nephrotoxic effects 18
Nervous systems 27, 47
Neuraminidase 13
Neuroblastoma 88, 125, 452
Neurodegenerative disorders 51, 101, 173,
 174, 183, 275, 385
Neuroinflammation 28, 30, 40, 59, 175
 microglia-mediated 30
Neurons 27, 28, 29, 30, 174, 275
 catecholaminergic 29, 275
 dopaminergic nigrostriatal 29
 histaminergic 275
 serotonergic 29
Neuropathological conditions 51
Neuroprotective 27, 17, 30, 43, 54, 177, 183,
 222, 226
 actions 27
 agents 183
 effects 17, 30, 43, 54, 177, 222, 226
Neuro-regenerative effects 19
Neurotoxicity 42, 45
 activity inhibition 42
Neurotoxin-induced injury 30
Neurotransmitters 174
Nitric oxide synthase 11
NMR spectroscopy-based analysis methods
 206
Non-communicable diseases (NCDs) 385
Non-covalent 40, 75
 DNA interactions 75
 interactions 40
Non-small cell lung cancer (NSCLC) 73, 83
Non-steroidal anti-inflammatory drug
 (NSAIDs) 100, 315, 317
Non-tuberculosis mycobacterial (NTM) 94
Novel biorefinery technologies 202
Nuclear magnetic resonance (NMR) 206, 207,
 208

O

Obesity-related diseases 10
Oesophageal cancer cells 427

Subject Index

Oestrogenic activity 412
Oils 30, 134, 182, 214, 395
 biocompatible 134
 olive 30, 395
Oligomeric 201, 220
 fraction 201
 plant polyphenols 220
Oncogenes 386, 392, 395, 455, 456, 463, 465
Oncoproteins 416
ORAC assay method 50
Organic anion transporters 16
Orthologue enzymes 366
Osteoporosis 222, 223, 412
Oxidation 4, 10, 80, 82, 150, 178, 179, 249,
 250, 390, 391, 392
 fatty acid 10
Oxidative 10, 174, 202
 enzymes 202
 injuries 10, 174
Oxidative stress 2, 12, 13, 28, 29, 30, 37, 52,
 56, 59, 221, 262
 conditions 221
Oxidised low-density lipoproteins 402
Oxygen 8, 10, 158, 293, 301, 385, 454
 atom, exocyclic 301
 reactive 385

P

PAMPA-BBB assay 54
Paracetamol, antipyretic drug 334
Parkinson's diseases 12, 27, 174, 175, 189,
 226, 250, 255, 267, 275
Pathologies 18, 19, 28, 59, 60, 177, 219, 275,
 385, 422, 423, 424
 age-related brain 28
 multifactorial 60
 neurodegenerative 275
Pathways 1, 14, 28, 29, 59, 74, 75, 89, 113,
 177, 204, 225, 256, 258, 385, 388, 393,
 408, 438, 439, 450
 biosynthetic 74, 204
 caspase-dependent 89
 epigenetic 439, 450

Medicinal Chemistry Lessons From Nature, Vol. 1 503

 intrinsic apoptosis 393
 metabolic 1, 14, 225, 388
 pro-apoptotic calcium signalling 256
 stress-response 385
PEG 122, 261
 biocompatible 122
 pterostilbene derivatives 261
Peroxidation 2, 454
 inhibiting lipid 2
Phenol CA inhibitory properties 348
Phenolic 3, 173, 223, 355, 369, 370
 inhibitors 369
 lactone 355
Phenols, synthetic 365, 373
Phosphoglycerate mutase 86
Photosensitizer 120, 121
 fluorescent 121
Phthalocyanine 121, 122
 fluorescent photosensitizer 121
Phytoestrogens 13, 223, 412
 dietary 13
Phytoestrogens pathway 7
Pinoresinollariciresinol reductase 204
Plant metabolites 189
Polymerisation 197, 462
 microtubule 462
Polyphenolics 1, 4, 147
Polyphenols 44, 220, 263
 lipophilic 44
 natural antioxidant 263
 oligomeric 220
Post-translational modification (PTM) 386,
 387, 388, 389, 390, 391
PPAR signaling pathway 225
Processes 3, 12, 29, 86, 115, 197, 202, 321,
 384, 386, 408
 apoptotic 408
 biorefinery 202
 biosynthetic 86
 epigenetic 384, 386
 hydrolytic 321
 metabolic enzymatic 115
 metastatic 3, 12
 neuroinflammatory 29
 radical polymerisation 197

Prodrugs, glycosylated 254
Products 3, 14, 19, 196, 218, 220, 223, 226,
253, 254, 275, 389, 427
 cosmetic 3
 genetic 427
 mono-methylated 389
 natural food 220
Progression, osteoporosis 13
Prokaryotes 298
Properties 9, 30, 34, 52, 56, 60, 74, 92, 102,
112, 150, 221, 224, 226, 249, 279, 307,
384, 393, 397, 412, 454, 455
 anti-aging 249
 anti-angiogenic 393
 anti-biotic 224
 anti-diabetic 30
 anti-inflammatory 9, 52, 221, 454
 antimycobacterial 150
 antioxidative 102
 antiproliferative 384, 397
 anti-protozoal 224
 biometal chelating 279
 haemolytic 92
 immunostimulating 74
 lipophilic 60
 metal chelating 34, 56
 neuroprotective 30, 226
 oestrogenic 412
 photoactivaetal antitumor 307
 phytoestrogen 455
 theranostic 112
Prostate cancer 13, 408, 413, 416, 441, 455
 progression 13
Prostatic intraepithelial neoplasia (PIN) 455
Proteasome degradation 397
Protective effects 226, 454
 cardiovascular 454
Proteins 2, 12, 15, 16, 54, 75, 88, 156, 174,
386, 387, 388, 390, 392, 393, 394, 397,
406, 430, 437, 438, 439, 440, 444, 455,
456
 aggregation 12
 amyloid 174
 anti-apoptotic 393, 438
 degradation 54

epigenetic 387, 397, 406, 430, 437, 439
heat shock 75
 kinases 386, 392, 393
metastasis-associated 455
mitogen-activated 12
transport 15
tumor suppressor 88
tumour suppression 456
 tyrosine-phosphatases (PTPs) 156
Pseudomonas aeruginosa 219
Pterostilbene, bioavailable derivative 455
Putative mechanisms 74

Q

Quantitative structure activity relationship
(QSAR) 152

R

Racemic mixtures 431
Radical 11, 12, 74, 101, 174, 175, 208, 220,
393, 454
 cation assay 208
 oxygen species (ROS) 11, 12, 74, 101, 174,
175, 220, 393, 454
Radical scavenging 56, 59, 393
 ability 59
 properties 393
 tests 56
Radiotherapy 114
Raman spectroscopy 206
Reaction 9, 16, 18, 19, 207, 251, 259, 262,
264, 265, 298, 300, 309, 331, 391, 441
 biosynthetic 331
 chlorination 262
 dependent dioxygenase 391
 enzymatic 264
 metabolic 331, 441
 phosphitylation 207
Reactive oxygen species production 275
Reduced chalcones 162
 sulfanilamide-substituted 162

Subject Index

Reduced toxicity 149
Refractive index detectors 208
Regulation, miRNAs 387
Regulation processes 300
Release 3, 10, 57, 101, 120, 135, 136, 225, 401
 cytokine 10
 mitochondrial 401
Replication, genomic RNA 13
Response 83, 88, 428
 chemotherapy 88
 innate-immune 83
 mediated DNA damage 428
Resveratrol 9, 258, 264, 266
 caffeic acid conjugate 266
 esterification of 258, 264
 isomers 9
 phosphoramidites 264
Rheumatoid arthritis 12, 317
Risk, cardiovascular 8

S

Saccharomyces cerevisiae 365
Scavenge radicals 9
Scavenging 175, 208
 radical 208
 superoxide radicals 208
Schrodinger's software 177
Semisynthetic methods 92
Serotonin, oxidizes 29
Signaling pathways 175, 225
Signal transduction 2
Silico 165, 179, 395, 402, 403, 406
 analysis 165, 179
 docking 395
 screenings 402, 403, 406
Simian retro virus (SRV) 225
Skin 3, 130, 466
 aging 3
 cancer 3, 466
 melanoma 130
Small antimicrobial peptidomimetics (SAPs) 91, 92

Medicinal Chemistry Lessons From Nature, Vol. 1 505

Squamous cell carcinoma 417
Stilbenoid-derived molecules 267
Stress 54, 55, 199
 mechanical 199
Structure(s) 9, 14, 33, 34, 39, 41, 45, 47, 49, 52, 53, 73, 74, 95, 96, 147, 148, 149, 158, 160, 161, 272, 302, 334, 405
 activity relationship (SAR) 9, 14, 73, 74, 95, 96, 147, 148, 149, 158, 160, 161, 272, 302, 334
 of alkylated RSV derivatives 53
 of carbazole-RSV hybrids 39
 of clioquinol-RSV hybrids 45
 of deferiprone-RSV hybrids 49
 of furocoumarin-PTR hybrids 41
 of imidazole-RSV hybrids 33
 of maltol-RSV hybrids 34
 of quercetin 405
 of tacrine-RSV hybrids 47
 of tyrosine-RSV hybrids 52
Structures of resveratrol 31, 264, 457
 phosphoramidites 264
Sulfonamide inhibitor acetazolamide 312
Superoxide dismutase 89
Susceptibility, metabolic 452
Suzuki-coupling 149
Synthesis 30, 32, 157, 213, 222, 224, 249, 250, 252, 259, 261, 262, 263, 264, 265, 313, 315, 400, 430, 431, 432, 437
 asymmetric 437
 enantioselective 431
 mycolic acid 157
 of coumarin 315
 of glycosylated coumarins 313
 of lignin nanotubes 213
 of resveratrol-Aspirin hybrids 265
 regioselective 400
Synthetic coumarins 308
Systems 82, 136, 249, 261, 385
 lymphatic 82
 nanoparticulate delivery 136
 pH-sensible target delivery 136
 respiratory 385
 resveratrol-derived semisynthetic 249

tellurium-containing natural-products-derived 261

T

Target(s) 165, 276, 289, 455, 456
enzymes 289
epigenetic 455, 456
putative 165, 276
Tea polyphenols 424, 428
green 428
Techniques, spectroscopic 206
Therapeutic agents 120, 173, 275
Therapy 121, 300
memory 300
photodynamic 121
Thermal stability 211
Thin layer chromatography (TLC) 151
Thioredoxin reductase 262
Thioxocoumarins 298, 318, 332
Toxicity 9, 18, 53, 115, 116, 145, 146, 154, 161, 166, 224, 226, 254
anti-inflammatory 224
of flavonoids 18
Toxicodendron vernicifluum 278
Traditional Chinese medicinal herb 30
Transcellular transport 15
Transcriptional silencing 410
Transcription factors 9, 86, 386, 410
Transmembrane isozymes 354
Transmission electron microscope 49
Traumatic brain injury (TBI) 226
Tryptophan fluorescence quenching assay 435
Tuberculosis 93, 145, 362, 363, 364
drug-resistant 145
multidrug-resistant 145
Tuberculous granulomas 158
Tubulin 122, 123, 125, 132, 460
binding assay 132
inhibition 122, 125
inhibitory activity 123, 460
polymerisation inhibition 460
Tubulin polymerization 112, 115, 119, 123, 127, 128, 129, 132
assay 132

inhibitors 119
Tumor(s) 47, 74, 116, 117, 120, 134
bone marrow 117
growth 74, 134
necrosis factor 47
neovascularization 116
neuroendocrine 117
transplanted mammary 134
vasculature 116, 120, 134
Tumour 30, 31, 47, 395, 398, 401, 413, 414, 416, 417, 419
necrosis factor (TNF) 47, 395, 413, 416
suppressing genes (TSGs) 30, 31, 395, 398, 401, 414, 417
suppressor 419
Tumorigenesis 317

U

UV-spectroscopy 208

V

Vancomycin 93
Vascular 88, 112, 113, 116, 117, 254, 393, 394
disrupting agent (VDA) 112, 113, 116, 117
endothelial growth factor (VEGF) 88, 254, 393, 394
Vibrio cholerae 366
Vilsmeier-Haack reaction 154

W

Waals 40, 46, 288
contacts 46
interactions 40, 288
Water, deionised 212
Whole-cell screening assay 147
World Health Organization (WHO) 146, 385

X

Xanthine oxidases (XO) 393



Simone Carradori

Prof. Simone Carradori has carried out his scientific work in Medicinal Chemistry collaborating with several foreign departments. Currently, he is an associate professor at the Department of Pharmacy of “G. d’Annunzio” University of Chieti-Pescara (Italy). The scientific activity is mainly focused on the characterization and synthesis of natural/ synthetic derivatives with potential biological activity and is documented from over 225 papers in international peer-reviewed journals, 6 book chapters, 1 European patent and participations in numerous conferences as invited lecturer. Furthermore, he is “Visiting Professor” at “Faculty of Pharmacy of Bezmialem Vakif University” (Istanbul, Turkey) and member of the PhD committee at “G. d’Annunzio” University of Chieti-Pescara.

He is Editor-in-chief of “Anti-Cancer Agents in Medicinal Chemistry” (Bentham Science Publishers), co-editor of “Current Medicinal Chemistry” (Bentham Science Publisher) and “Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry” (Bentham Science Publishers).